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A B B R E V I A T I O N S 
Abs Antibodies 
Act D Actinomycin D 
A T C C American type culture collection 
CPS Capsular Polysaccharide 
CTL Cytotoxic T lymphocyte 
C Y Cyclophosphamide 
Dox Doxorubicin 
E A T Ehrlich ascites tumor 
ECL Enhanced chemiluminescence 
ELISA Enzyme-linked immunosorbent assay 
E R K Extracellular-signal-regulated kinase 
FCS Fetal calf serum 
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h Hour 
HBSS Hank's balanced salt solution 






IDO Indolamine 2,3-dioxygenase 
JNK Jun N-terminal kinase 
kDa Kilo-dalton 
L A K Lymphokine-activated killer 
LBP LPS-Binding Protein 
LC50 50% lethal concentration 
II 
LDso 50% lethal dose 
LPS Lipopolycharide 
%• 
M.W. Molecular weight 
m A Milliampere 
M A P K Mitogen-activated protein kinase 
M E K MAPK7ERK kinase 
M E K K MAPK/ERK kinase kinase 
M H C Major histocompatibility complex 
min Minute 
N G F Nerve growth factor 
N K Natural killer 
nm Nanometer 
PBS Phosphate-buffered saline 
PAF < Platelet-activating-factor 
PMSF Phenylmethylsulfonyl Fluoride 
PS Penicillin-Streptomycin 
rmTNF-a Murine recombinant tumor necrosis factor — 
alpha 
rpm Revolutions per minute 
RPMI 1640 medium Rosewell park memorial institue tissue culture 
medium 1640 
S.D. Standard deviation 
SAPK Stress-activated protein kinase 
SDS-PAGE (Sodium dodecyl sulfate)-Polyacrylamide gel 
electrophoresis 
TBS-T Tris buffer saline in Tween-20 
T E M E D N,N,N',N'-tetramethylethylenediamine 
TIL Tumor-infiltrating lymphocyte 
III 
TNF-a Tumor necrosis factor-alpha 
V Voltage 
聲. 
w/v weight / volume 





Capsular polysaccharides (CPS) are polysaccharides isolated from the capsule 
of the bacteria Klebsiella pneumoniae. Two of these polysaccharide antigens, 
including serotype K1 and K24, have been studied in this project. They are 
characterized to contain mainly carbohydrates with high uronic acid content and trace 
amount of protein. They are homogeneous and have well-defined structures. The 
culture of these serotype bacteria and the isolation of their CPS were reproducible. 
In the previous studies in my laboratory, K1 and K24 CPS were found to 
r 
possess many immunomodulatory and anti-tumor activities. In m y study, both K1 
and K24 CPS could greatly induce the tumor necrosis factor-alpha (TNF-a) 
production from murine peritoneal macrophages. It has been shown that K1 and K24 
CPS activated the expressions of mitogen-activated protein kinase (MAPK) signaling 
proteins, including ERK1 and ERK2, p38 and JNK, in murine macrophages. Also, 
CPS was able to suppress the growth ofEAT cells in vivo and prolong the survival of 
EAT bearing mice. However, CPS showed a slightly cytotoxic effect on tumor cells 
in vitro. W e believed that the cytotoxic effect of CPS on tumor cells was by 
activating the secretion of cytokines such as TNF-a, thereby killed the tumor cells. 
The studies of CPS may have important implication in the immunotherapy of cancer. 
V 
Abstract 
The effect of combined treatment of immunotherapy and chemotherapy on 
, tumor cell was investigated. K1 and K24 were used in immunotherapy and the 
chemotherapeutic drugs including actinomycin D (Act D)，cyclophosphamide (CY) 
and doxorubicin (Dox) were used in chemotherapy. It was found that K1 and K24 
CPS augmented the effect of the chemotherapeutic drugs (Act D, C Y and Dox) on 
both the suppression of tumor cell growth in vivo and the prolonging of the survival 
of tumor-bearing mice. This indicated that CPS may be used as a useful adjuvant 
especially combined with chemotherapy using Act D, C Y and Dox in clinical 










根據本實驗室過往的研究 Kl 及 K24 CPS 具有很多免疫功能
的調控作用以及抗腫瘤的功能.由是次研究中亦發現，也及 K24
CPS 能刺激鼠性腹膜巨噬細胞製造大量的 α 型腫瘤壞死因子
(TNF-α) . 本研究亦證明，也及K24 CPS 能激發促細胞分裂劑蛋白
激晦 (MAPK) 的信息傳遞蛋白於鼠性巨噬細胞里的表達.這些信
息傳遞蛋白包括 ERKl 及 ERK2， p38 及 JNK. 同時， CPS 亦能抑壓 EAT
細胞於小鼠體內的生長及延長小鼠的壽命.不過，在離體實驗中，





除 上 述 外 , 我 們 亦 嘗 試 對 癌 細 胞 作 免 疫 及 化 學 相 結 合 治 療 
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In the first part of this chapter, the immunotherapy in cancer will be 
introduced. Next, the immunomodulatory and anti-tumor activities of plant 
polysaccharides, and the previous studies on the immunomodulatory effects of 
capsular polysaccharides (CPS) from Klebsiella pneumoniae will be shown. Finally, 
the activation of TNF-a production from macrophages by bacterial polysaccharides 
and the chemotherapy in cancer will also be discussed. 
1.1. Immunotherapy in Cancer 
The human immune system plays an important role in immunosurveillance 
against many invasive microorganisms and malignant cells. However, some cancer 
patients suffer from various kinds of immunosuppression if they are receiving 
radiotherapy and/or chemotherapy. These treatments severely suppressed the normal 
immune functions of cancer patients. Immunotherapy can help to restore the 
suppressed immune system of patients and is likely to be beneficial in cancer therapy. 
4 
Immunotherapy is one of the mainstreams of cancer research. The 
, developments in molecular techniques enhance the development of immunotherapy. 
For example, the proteins and peptides (e.g. cytokines) that regulate the immune 
system can now be precisely defined and produced in a highly purified state, allowing 
more specific testing to take place and larger scale clinical trials to be performed. 
The theoretical basis of current immunotherapy strategies involved the breaking 
ofthe host's immunological tolerance to the tumor. The host can recognize its tumor 
as non-self and mounts an effective response against it. 
1.1.2. Cytokines used in Immunotherapy in Cancer 
•r 
Cytokines are a group of low weight, soluble proteins, which act as 
messengers between cells across the extracellular environment. They exert a wide 
range of biological effects, particularly in cells of the immune and haematopoietic 
lineages. They mediate host responses to a number of inducing stimuli including 
infections, inflammation, normal cell proliferation，differentiation and repair 
(Aggarwal and Pocsik, 1992). Recently it has become clear that they are biologically 
active in a wide range of tissues including the endocrine, gastrointestinal and central 
nervous systems. Receptors on the surface of the target cell mediate cytokine 
activity; together with the cytokines themselves, most have been cloned and studied 
5 
at the molecular level. The research has highlighted key features of cytokine biology 
. and thereby enhanced our understanding of their therapeutic potential (Eisen, 1996). 
Many cytokines are found to be cytostatic and / or cytotoxic to tumor cells. They 
have been used in clinical trial to stimulate haematopoietic elements in the bone 
marrow and to exert both direct and indirect anti-tumor effects by modulating host 
immune and inflammatory responses. The anti-tumor immune responses and the 
clinical uses of cytokines will briefly introduced. 
1.1.2.1. Interferons (IFNs) 
There are three interferons: interferon-a (from leukocytes, < 
macrophages), interferon-P (from fibroblasts) and interferon-y (from T lymphocytes). 
IFN-a and IFN-p share a common receptor on the surface of the target cells, whereas 
IFN-y has its separate receptor. IFN-y activates macrophages and T cells, resulting 
the secretion ofIL-l, IL6 and TNF-a, induction of Class I and Class II M H C antigens 
on the cell membrane. Both IFN-a and IFN-P also exhibit such immunomodulatory 
effect but the effect is less potent than IFN-y (Fossa, 1996). IFN is produced as a 
defensive response to tumors and microbial antigens in humans. Interferons induce 
anti-viral, anti-microbial, anti-tumor and immunomodulatory effects (Table 1.1). 
IFNs have been used in the treatment of viral diseases, e.g. hepatitis C (Omata et al., 
6 
, Table 1.1. Interferons — Mechanisms of Action (Fossa, 1996). 
Anti - viral 
immunomodulatory 
(Direct: activation of cellular immune response) 
(Indirect: increase of the tumor cells' antigenicity) 
Modulation of differentiation 
Anti-proliferative 
Cytotoxic 
Oncogene depression {c-myc, N-ras, c-Src, p53, c-fos) 
Suppression of angiogenesis 
< 
7 
1991; Schvarcz et aL, 1991), and condyloma accuminata (Reichman et al.，1990). 
‘ IFNs also exert clinically useful anti-tumor activity in several malignancies (Table 
1.2). 
The anti-tumor effect can be mediated as direct cytostatic activity, for 
example, reduction of cell proliferation, interference with cellular metabolism (Fossa, 
1996). IFNs can also be directly cytotoxic, leading to cell lysis (Baron et al., 1991). 
They produce indirect anti-tumor effect by the modulation of the immune response, 
such as enhancement of tumor-associated cellular surface antigens, induction of 
antibodies to tumor cells, enhancement of tumor cytotoxicity by macrophages, of 
natural killer cells and of T lymphocytes (Baron et al., 1991). IFN-a is in current 
< 
routine clinical use in many cancer treatments, such as hairy cell leukemia (Kurzrock 
et aL, 1991), multiple myeloma (Westin, 1991: Mandelli, 1990)，and renal cell 
carcinoma (Muss, 1991). 
The anti-tumor effect of IFN_P is cytostatic rather than cytotoxic. Its 
antiproliferative effects can be demonstrated by alteration of oncogene activity (Pape 
et al., 1989) and induction of tumor cell differentiation in certain cell lines fNair et 
al., 1994). Clinical trials ofIFN_P have been conducted in treatment of melanoma 
(Abdi et aL, 1988) and breast cancer (Buzzi et aL, 1992). 
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Table 1.2. Anti-tumor Activity ofIFNs in Human Malignancies (Fossa, 1996). 
' Lymphoproliferative disorders 
Chronic myelogeneous leukemia 
Hairy cell leukemia 
Nodular lymphoma 
T cell lymphoma 
Multiple myeloma 
Solid tumors 








IFN-y is a potent activator of macrophage,which upregulates the receptors for 
• TNF, lymphotoxin (LT), and IL-1 (Balkwill, 1989). One proposed mechanism 
mediating the anti-proliferative effects of IFN-y in tumor cells is the induction of the 
enzyme indolamine 2,3-dioxygenase (IDO). Studies have shown that IFN-y induces 
IDO activity in cell lines. IFN-y can also promote differentiation in tumor cell lines 
(Oberg et al., 1991; Montalso et al., 1992) as evidenced by the upregulation of both 
Class I and Class II M H C antigens (Balkwill, 1989). The expression of tumor-
associated antigens, such as carcinoembryonic antigen (Kantor et al., 1989) and the 
carbohydrate antigen 19-9 (0'connell et al., 1989), are also modulated by IFN-
y. These cell surface changes induced by IFN-y suggest other potential uses in cancer 
therapy. For exampk, upregulation of M H C class II antigens, and tumor-associated 
antigens, may enhance immunogenicity of tumors (Malik, 1996). 
The side effects of IFN-p and IFN-y are similar. They are flu-like symptoms, 
nausea and vomiting, and fatigue with prolonged administration. Transient and renal 
dysfunction will occurred when there is high-dose administration (Malik, 1996). 
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1.1.2.2. Interleukins (ILs) 
•* 
Interleukin 1 (IL-1) is a pro-inflammatory cytokine mainly produced by 
activated macrophages. IL-1 production is generally considered to be a consequence 
of inflammation. It induces the expression of a variety of genes and the synthesis of 
several proteins that, in tum, induce acute and chronic inflammatory changes. IL-1 is 
also the prototypic "alarm" cytokine in that it brings about increases in a variety of 
defense mechanisms, particularly immunologic and hematologic responses 
(Dinarello，1991). However, IL-1 can be produced by a variety of cells including 
monocytes, macrophages, osteoblasts, keratinocytes, Kupffer cells, hepatocytes, 
thymic and salivary gland epithelium, fibroblasts, and glial cells. 
< 
Experimental data in mice have shown that IL-1 is able to recruit anti-tumor 
immune activity (Fomi et al., 1989). Furthermore, IL-1 both directly and indirectly 
stimulates haematopoietic progenitors and enhances production of other cytokines in 
vitro and in vivo (Crown et al., 1993). Clinical investigation of IL-1 has focused on 
its myeloproliferative and myeloprotective properties. Two phase I clinical studies 
indicated that both IL-la and IL-ip stimulate haematopoiesis in patients undergoing 
myelosuppressive chmotherpy or with advanced malignancy (Crown et al, 1991; 
Smith et al, 1992). Multiple daily cytokine injections of IL-1 reduced bone marrow 
precursor cell sensitivity to radiotherapy and chemotherapy (Dalmau et al., 1992). 
11 
Also, in a phase II clinical study in patients undergoing myelosuppressive 
、 chemotherapy, IL-1 accelerated recovery of granulocytes and platelets by inducing 
colony stimulating factors (Kawai et al.，1994). 
Interleukin 2 (IL-2) is a key regulatory cytokine responsible for stimulating 
the host reaction to foreign molecules and microbes (Smith, 1988). It is a lymphokine 
synthesized and secreted primarily T helper lymphocytes that have been activated by 
stimulation with certain mitogens or by interaction of the T cell receptor complex 
with antigeny^MHC complexes on the surfaces of antigen-presenting cells (Morgan et 
al., 1976; Hatakeyama et al., 1990). IL-2 consists of 133 amino acids and has a 
molecular mass of 15 kDa. Its gene is localized in the long arm of chromosome 4 and 
< 
its synthesis is regulated at the transcriptional level (Fletcher et al, 1987). IL-2 is also 
called T cell growth factor because it activates the proliferation ofT cell (Smith et al., 
1980). IL-2 acts as both autocrine and paracrine growth factors on T cell 
proliferation. IL-2 stimulates the antigen-nonspecific responses mediated by natural 
killer fNK) cells and monocytes, and as a result of its effects on T cells and B cells, 
IL-2 is crucial for the generation of antigen-specific reactivity. All of these attributes 
make IL-2 a prime candidate as an immunotherapeutic to be tested for efficacy in 
wide range of diseases, including cancer (Smith, 1994). The significance of IL-2 on 
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Figure 1.1. The significance of IL-2 on cellular interactions and immune activation 
for tumor rejection (Smith, K.A., 1994). 
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1.1.2.3. Tumor Necrosis Factor-Alpha (TNF-a) 
* . 
Tumor necrosis factor-alpha (TNF-a) is a protein of 157 amino acids that is 
produced mainly by monocytes, activated macrophages. TNF-a is so named because 
it can cause haemorrhagic necrosis of the murine sarcoma Meth A and regression of a 
variety of other murine tumors (Carswell et al., 1975; Haranaka et al., 1984; 
Brouckaert et al., 1986). It is also called cachetin because it was found that it was the 
serum factor from endotoxin primed macrophages which caused abnormal lipid 
metabolism (cachexia) in mice (Beutler et al., 1985). 
TNF-a is usually referred to as "inflammatory cytokine" since it acts as a 
central role in initiating (along with IL-1) the cascade of other cytokines and factors 
that make up the immune system's response to infection and sometimes to cancer. 
TNF-a stimulates T cell proliferation, enhances activity of natural killer 0S[K) cells, 
induces macrophage-mediated cytotoxicity and is directly cytotoxic to some tumor 
cells. TNF-a increases M H C Class I and II antigen expression, which may be 
important in direct and indirect cytotoxicity (Boshoff and Jones, 1996). TNF-a also 
stimulates endothelial cells to release inflammatory mediators including IL-1, 
platelet-activating-factor (PAF) and interleukin-6 (IL-6). TNF-a induces the 
expression of adhesion molecules on vascular endothelium, thereby enhancing 
• 
migration and accumulation of leukocytes in areas of inflammation (Vassalli, 1992). 
14 
, In vitro studies of TNF-a cytotoxicity showed that TNF-a is cytotoxic to 
many epithelial cancer cell lines (Haranaka and Satomi, 1981). In vivo TNF-a causes 
regression of a wide range of murine tumors and also has activity against human 
tumors heterotranspanted as xenografts in immune-deprived mice (haranaka et al., 
1984; Creasey et al., 1986). The combination of TNF-a and IFN-y in cancer 
treatment has been shown to be particularly effective in experimental animal models 
(Malik and Balkwill, 1991). This may due to the synergistic effect between TNF-a 
and IFN-y on the potentiation of the tumoricidal activity of activated macrophages. 
Phase I clinical trial have been carried out on colorectal carcinomas and soft tissue 
sarcomas and the tumor regressions were resulted (Borden and Sondel, 1990). Also, 
the cytotoxicity of TNF-a could be potentiated by other agents including cytokines, 
chemotherapeutic drugs, radiation and hyperthermia. (Table 1.3). 
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Table 1.3. Agents shown to be synergistically cytotoxic with TNF in vitro 
, (modified from Spriggs, 1991) 
1. Cytokines Interferon-a, -p, -y 
interleukin-4 
2. Chemotherapeutic Drugs 
a. Inhibitors of m R N A synthesis Actinomycin D 
5-Fluorouracil 
b. Mitosis inhbitors 
c. Alkylating agents Cyclophosphamide 
Cisplatin 
Ionizing radiation 






1.2. Immunomodulatory and Anti-tumor Activities of Plant Polysaccharides 
* 
In traditional medicine, extracts of certain fungi and higher plants are applied 
for the treatment of cancer. Many of these extracts have been found to modulate 
various immunological functions (Zhao et al., 1990; Kumazawa et al., 1982), and 
some of them serve as inhibitors or killers of tumor cells (Kumazawa et al., 1982; 
Ebina et al., 1988; Miyazaki et al., 1979). In many cases, these activities are due to 
their polysaccharide components (Wong et al., 1994b). It is believed that these 
polysaccharides exert their anti-tumor activities by mediating the immune system of 
the host (Wong et al., 1994b;Wong et al.,1994b). 
Immunomodulatory polysaccharides extracted from natural plant have been 
found to possess a wide variety of effects on the immune system including the 
activation of macrophages, N K cells, lymphokine activated killer (LAK) cells, tumor-
infiltrating lymphocytes, cytotoxic T lymphocytes (CTL), T lymphocytes, and B 
lymphocytes (Table 1.4). They also stimulate the production of anti-tumor cytokines 
including interferon-y, interleukins, tumor necrosis factor-a and colony stimulating 
factors (Table 1.4). Stimulation of bone-marrow haematopoiesis is also one of the 
immunomodulatory activities of these polysaccharides (Table 1.5). 
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Table 1.4. The immunological activities (1) of immunomodulatory polysaccharides 
isolated from various medicinal plants, (modified from Wong, C.K., 
1994b) 
Active fractions or 
Immunological effect Medicinal plant component 
Stimulation of immune cells 
Mitogenic for lymphocytes Pseudostellaria heterophylla PH-I 
Activation of T lymphocytes Lentinus edodes p( 1,3)-glucan 
Activation ofB lymphocytes Coriolus versicolor PSK 
Macrophage activation Radix bupleuri Aqueous extract 
Activation of cytotoxic 
effector cells 
Cytotoxic T lymphocytes Lentinus edodes P(l,3)-glucan 
Natural killer cells Coriolus versicolor PSK 
Lymphokine activated killer Astragalus membranaceus F3 
cells Lentinus edodes Lentinan 
Tumor infiltrating Lentinus edodes P( 1,3)-glucan 
lymphocytes Pseudostellaria heterophylla PH-I C 
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Table 1.5. The immunological activities (2) of immunomodulatory polysaccharides 
isolated from various medicinal plants, (modified from Wong, C.K., 
1994b) 
Active fractions or 
Immunological effect Medicinal plant component 
Stimulation of cytokine 
production 
Interferon-y Lentinus edodes p(l,3)-glucan 
Interleukin-1 Coriolus versicolor PSK 
Interleukin-2 Schizophyllum commune Schizophyllan 
Interleukin-3 Lentinus edodes p(l,3)-glucan 
Tumor necrosis factor-a Pseudostellaria heterophylla PH-I Cb 
Coriolus versicolor PSK 
Colony stimulating factors Pseudostellaria heterophylla PH-I Bb 
Stimulation of bone-
marrow haematopoiesis 
Epimedium sagittatum Crude extract 
Pseudostellaria heterophylla PH-I Ba 
Lentinus edodes p(l,3)-glucan 
Coriolus versicolor PSK 
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Some plant-derived polysaccharides have been found to have anti-tumor activity in 
， clinical studies (Mizutani and Yoshida，1991). For example, PSK, a protein-bound 
polysaccharides isolated from Coriolus vesicolor, can prolong the disease-free 
intervals in colorectal cancer patients after surgery (Torisu et al., 1990) and can 
increase the life-span of patients with recurrent stomach cancer when combined with 
mitomycin C and 5-fIuorouracil (Tsukagoshi et al., 1984). Some polysaccharides 
were found to restore immunosuppression induced by the anti-tumor agent, 
cyclophosphamide, for example, the polysaccharide peptide (PSP) extracted from 
Coriolus vesicolor (Qian et al., 1997) and Z-100, a polysaccharide-rich extract from 




1.3. Previous Studies on the Capsular Polysaccharides (CPS) from Klebsiella 
, pneumoniae 
Klebsiella are gram-negative bacteria which are rod shaped, non-motile and 
encapsulated (Lee, 1987; Orskov and Orskov, 1984). They cause pneumonia, 
bacteremia, infections of urinary and respiratory tract (Lee, 1996). Among the 
member of the genus Klebsiella, Klebsiella pneumoniae is the most common type 
which causes pneumonia in human (Lee, 1996). An important characteristic of 
Klebsiella pneumoniae growth is the production of capsular polysaccharide (CPS). A 
thick CPS layer, referred to as a capsule, envelops these bacteria and resists the 
protective host defenses (Simoons-Smit et aL, 1986; Williams et al., 1983). CPS 
< 
contributes to the resistance to opsonophagocytosis in Klebsiella pneumoniae 
(Domenico et al.，1994). CPS also binds and neutralizes antibodies that would 
otherwise attach to an opsonize bacteria (Cryz et al., 1986). 
CPS antigens were also named K-antigens. At least 82 different known K-
antigens, which are vary in structures and biochemical compositions, were identified 
(Orskov and Orskov, 1984). Previous studies on Klebsiella capsular polysaccharides 
were concentrated on their vaccine potential (Cryz, Jr. et aL, 1985a; Cryz, Jr. et aL, 
1985b). Among the various Klebsiella strains, K1 (Choy et al., 1996), K7 and K24 
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capsular antigens were well studied for their immunomodulatory and anti-tumor 
- activities. 
K1, K7 and K24 CPS antigen were extracted from Klebsiella pneumoniae 
type 1，type 7 and type 24 respectively. All of them were purified by Cetavlon and 
alcohol precipitation. They were characterized to contain mainly carbohydrate with 
high uronic acid content and trace amounts of protein. Among the three CPS, K1 had 
the highest uronic acid content (30.2 %). High uronic acid content of CPS may 
contribute to their immunomodulatory and anti-tumor activities (Espevik et al., 
1993). They were homogenous in nature and they have well-defined repeating units. 
r 
All three CPS were found to exert various immunomodulatory activities. 
They exhibit potent mitogenic activities both in vitro and in vivo. Both K1 and K24 
increased the interleukin-1 (IL-1) production of thioglycollate-elicited murine 
peritoneal macrophage. However, only the latter increased the interleukin-2 
production of splenocytes. All three CPS were good immunopotentiators on 
macrophages. They enhanced the in vivo migration of murine macrophage into the 
peritoneal and enhance the release of nitric oxide fNO) from the macrophage. 
Furthermore, they stimulated the proliferation of murine bone marrow cells and even 
induced the cells into macrophage-like cells in vitro. 
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K1, K7 and K24 also exhibit various anti-tumor activities. It was found that 
- all of them augmented the tumor necrosis factor (TNF-a) production in vitro (from 
thioglycollate-elicited peritoneal macrophages) and in vivo (from mouse serum). 
They also activated the effector cells involved in anti-tumor activities such as natural 
macrophages (mentioned above), killer fNK) cells, lymphokine-activated killer 
(LAK) cells and tumor-infiltrating lymphocytes (TILs). 
K1 exerted little cytostatic activities on various tumor cell lines, such as EAT 
carcinoma, L929 fibrosarcoma and WEHI-164 fibrosarcoma, in vitro. On other hand, 
K7 exhibited a dose-dependent suppressive effect on the proliferation of various 
myeloid leukemia cells, including M l cells and WEHI-3B JCS, in vitro. K24 also 
< 
exerted a dose-dependent suppressive effect on the proliferation of EAT carcinoma in 
vitro. Finally, all of them suppressed EAT carcinoma growth significantly in the 
peritoneal cavities of BALB/c mice. The properties of K1, K7 and K24 were 
summarized in Table 1.6. 
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Table 1.6. Summary of The General Properties, Immunomodulatory and 
、 Anti-tumor Activities in K1, K7 and K24 Capsular Polysaccharides 
m ^ ^ 
1. General Properties 
Extraction and Purification Relatively simple 
Composition Mainly carbohydrate with high uronic acid content 
Structure • Homogenous, have defined repeating units 
Toxicity Low 
2. Immunomodulatory Activities 
Mitogenic Activities + + + 
IL-2 Production - ^ + 
IL-1 Production - N/A + 
Macrophage Migration + + + 
Macrophage N O Production + + + 
Proliferation & Differentiation + + + 
of Bone Marrow Cells 
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、 m ^ ^ 
3. Anti-Tumor Activities 
TNF Production in vitro & in + + + 
vivo 
Activation ofNK cell + + + 
Activation pf L A K cell + + + 
Activation ofTIL + + + 
Cytostatic Activities in vitro Slightly on On murine On EAT 
various tumor myeloid carcinoma 
cell lines leukemia M l 
& WEHI-3B 
JCS leukemia 
Anti-tumor Activities^ m vivo Potent on EAT carcinoma 
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1.4. Activation of TNF-a Production from Macrophages by Bacterial 
,. Polysaccharides 
Although it was found that K1 and K24 capsular polysaccharides could 
stimulate macrophages to produce various cytokines, such as IFN-y, IL-2 and TNF-a, 
the mechanism of how this activation can be achieved is unknown. It is believed that 
capsular polysaccharides stimulate the cytokine productions from macrophages by 
mimicking the effect of lipopolysaccharide (LPS) on the macrophages. LPS, a 
surface component of gram-negative bacteria, is released on host infection and causes 
tissue injury and shock (Morrison and Ryan, 1979). The adverse effects of LPS are 
mediated by cytokines that are produced by LPS-activated macrophages. One of the 
< 
most important cytokine is TNF-a (Beutler et al., 1985). Therefore, many 
researchers studied the mechanism of how LPS could induce TNF-a production from 
macrophages (Swantek et aL, 1997; Geppert et al., 1994). 
It has been found that LPS in the bloodstream binds to LPS-binding protein 
(LBP) (Tobias et al., 1986). Interaction of LPS-LBP complexes with macrophages 
induces the synthesis of TNF-a by the macrophages (Schumann et al., 1990). The 
receptor in macrophages for LPS-LBP complexes is CD14 (Wright et aL,1990), 
which is a glycosylphosphatidylinositol (GPI)-linked membrane-associated protein 
whose expression is limited to monocytes and macrophages. The signaling pathways 
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utilized by LPS to induce TNF-a biosynthesis are unknown but are believed to be 
, dependent on the activation of tyrosine kinases (Geng et al., 1993; Novogrodsky et 
aL, 1994; Weinstein et al., 1991), which often involves the subsequent activation of 
distinct mitogen-activated protein kinase (MAPK) signaling pathways. 
The mitogen-activated protein kinases (MAPKs) are serine/threonine protein 
kinases that transduce signals originating from extracellular events, such as cell 
surface receptor engagement, culminating in the regulation of a cellular response, 
such as growth or differentiation (Seger and Krebs, 1995; Kyriakis and Avmch, 
1996). The M A P K s include the extracellular signal-regulated kinases (ERKs), the c-
Jun N-terminal kinase/stress activated protein kinases (JNK7SAPK), and the p38 
< 
M A P K s (p38s). These three families of M A P K s form three parallel signaling 
cascades activated by distinct and sometimes overlapping sets of stimuli. 
The best-characterized M A P K pathway, the E R K pathway, consists of Raf, 
M E K 1 and MEK2, and ERK1 and ERK2 (Cobb and Goldsmith, 1995) and is 
activated in response to growth factors, including nerve growth factor fNGF), 
epidermal growth factor, and insulin (Boulton et al., 1991). Also, it has been shown 
that members of the E R K pathway are involved in the regulation of TNF-a 
production (Geppert et al., 1994). Another M A P K pathway involves the M A P K 
family member p38. p38 was cloned because its activation in monocytes was 
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specifically blocked by a drug which inhibited TNF-a translation (Lee et al., 1994) 
, and was cloned independently as a kinase activated by LPS (Han et al., 1994). The 
putative three-kinase cascade consists of unknown M E K K s , M E K 3 and M E K , and 
p38 (Derijard et al., 1995; Han et al.，1994; Han et al., 1996; Lee et aL，1994). A 
third M A P K pathway, the JNK/SAPK pathway，becomes activated in response to a 
various physiological and stress-related stimuli (Derijard et al., 1994; Kyriakis et aL, 
1994). The three-kinase cascade is believed to consist of MEKK-1, M E K 4 and 
JNK7SAPK (Kyriakis et aL, 1994; Sanchez et al., 1994). 
The three MAPKs, ERK, p38 and JNKs, differ in their responses to 
extracellular stimuli. In general, ERKs are activated by growth factors and phorbol 
< 
esters (Cobb and Goldsmith, 1995)，while the JNKs and p38s are activated by stress-
inducing agents or proinflammatory cytokines, such as TNF-a (Kyriakis and Avruch, 
1996). 
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1.5. Chemotherapy of Cancer 
, Chemotherapy is one of the most common treatment of cancer. Many drugs 
that have been tested in humans are found to be useful for the treament of patients 
with cancer. For anti-tumor drug treatment to be effective, several features must be 
present. The drug must reach the cancer cells, sufficiently toxic amounts ofthe drug 
(or its active metabolite) must enter the cells and remain there for a long enough 
period of time. The tumor cells must be sensitive to the effects of the drug, and all 
this must occur before resistance emerges. In addition, the patient must be able to 
withstand the adverse effects of treatment (Chabner, 1990; Cadman and Durivage, 
1990). Current-used chemotherapeutic drugs can be divided into several families 
including alkylating agents, plant alkaloids, anti-metabolites and anti-tumor 
< 
antibiotics (Table 1.7). 
1.5.1. Types of Chemotherapeutic Drugs 
1.5.1.1. Alkylating Agents 
Alkylating agents are highly reactive compounds that easily attach to different 
cell constituents. Under physiological conditions, alkylating agents are positively 
charged and they react with any molecules that are negatively charged or have 
regions of high electron density. In spite of the wide variety of negatively charged 
molecules that exit in cells, it is thought that D N A is the principal target site for 
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Table 1.7. Types of Chemotherapeutic Drugs and their Mechanisms ofAction 
, (Fischeretal., 1997) 
Drugs Mechanisms 
1. Alkylating Agents 
Cyclophosphamide D N A cross-linking 
Ifosfamide D N A cross-linking and chain scission 
Melphalan D N A cross-linking, alkylation of cellular thiols 
Procarbazine D N A alkylation, inhibits methyl group incorporation into 
R N A 
2. Plant Alkaloids 
Doxorubicin D N A intercalation, preribosomal D N A and R N A 
inhibition, alteration of cell membranes, free radical 
formation 
Etoposide ^ Inhibition of topoisomerase II 
Mitoxantrone D N A intercalation, Inhibition of topoisomerase II 
Vinblastine Tubulin binding (microtubule assembly inhibition and 
dissolution of mitotic spindle structure) 
3. Anti-metabolites 
Fluorouracil Inhibition of thymidylate synthase, an enzyme involved in 
conversion of deoxyuridylic acid to thymidylic acid 
Hydroxyurea Inhibition of ribonucleoside reductase (inhibits conversion 
ofribonucleosides to deoxyribonucleosides), thymidine 
incorporation into D N A and R N A repair 
Methotrexate Inhibits dihydrogolate reductase, thereby halting 
thymidylate and purine synthesis 
4. Antibiotics 
Actinomycin D Binds double-stranded D N A and inhibits R N A systhesis 
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alkylating agent activity (Calman et al., 1980). The primary action for most 
, alkylating drugs is via cross-linking of D N A strands. Replication of D N A and 
transcription of R N A are prevented (Colvin and Chabner, 1990). Alkylating agents 
play a significant role in the treatment of lymphoma, Hokgkin's disease, breast 
cancer, multiple myeloma, and other malignancies (Fischer et al., 1997a). 
1.5.1.2. Plant Alkaloids 
Many alkaloids of plant origin have been screened for potential anti-tumor 
activity. Plant alkaloids with anti-tumor activity are divided into several classes: 
topoisomerase inhibitors (e.g. doxorubicin, daunorubicin), mitotic inhibitors (e.g. 
r 
vinblastine, vincristine) and enzymes (L-asparaginase) (Fischer et al., 1997a). 
Topoisomerases are enzymes that break and reseal D N A strands (Bender et 
al., 1990). The plant alkaloid camptothecin and its analogues are specific in 
inhibitors of topoisomerase I. Etoposide，doxorubicin, daunorubicin and 
mitoxantrone are inhibitor of topoisomerase II (Table 1.7). These drugs form a stable 
complex by binding to D N A and topoisomerase enzymes, resulting in D N A damage 
that interferes with replication and transcription (Fischer et al., 1997a). Mitotic 
inhibitors, such as vinblastine and vincristine, exert their cytotoxic effects by binding 
to tubulin. This inhibits formation of microtubules, causing metaphase arrest (Bender 
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et al., 1990). L-Asparaginase is an enzyme product that acts primarily by inhibiting 
, protein synthesis by depriving tumor cells of the amino acid asparagine. Cells that 
have the ability to form their own asparagine, such as many normal cells, are not 
affected by L-asparaginase. L-Asparaginase is a foreign protein, is antigenic, and can 
cause serious hypersensitivity reaction (Fischer et al., 1997a) 
1.5.1.3. Anti-metabolites 
Anti-metabolites are anti-tumor agents that exert their effects largely in the 
synthetic phase of cell cycle (Table 1.7). They interfere with the synthesis ofDNA 
and RNA. Some anti-metabolites are structural analogues of normal metabolites 
< 
essential for cell growth and replication. This property allows them to be 
incorporated into D N A or R N A so that a false message is transmitted. Other anti-
metabolites inhibit enzymes that are necessary for the synthesis of essential 
compounds. In general, these agents have been most effective where cell proliferation 
is rapid. Some commonly-used anti-metabolites are fluorouracil, mercaptopurine and 
hydroxyurea 
1. 5.1.4. Antitumor Antibiotics 
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Anti-tumor drugs that are derived from microorganisms are called tumor 
antibiotics (Myers and Bender, 1990). Several of these drugs interfere with D N A 
� 
through intercalation, a reaction whereby the drug inserts itself between D N A base 
pairs. Some of the anti-tumor antibiotics have other mechanisms to exert anti-tumor 
effects, such as inhibition of topoisomerase enzymes, antimitotic effects, and 
alteration of cellular membranes. Most of the anti-tumor antibiotics appear to be cell-
cycle nonspecific agents (Fischer et aL, 1997a). 
• < 
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� 1.5.2. Chemotherapeutic Drugs in this Project 
1.5.2.1. Actinomycin D (Act D) 
Actinomycins were the first anti-tumor antibiotics to be clinically evaluated. 
Actinomycin D was isolated and introduced into clinical practice in 1954. It has a 
wide range of anti-tumor activity, and is one of the most active drugs on Wilms， 
tumor, cancers of the endometrium and ovary, and Kaposi's sarcoma (Calman et al., 
1980; Fischer et al., 1997b). The mechanism of action of actinomycin D is to bind 
double-stranded D N A and to inhibit R N A synthesis (DNA-dependent R N A 
< 
polymerase). The specificity of actinomycin D is determined by drug penetration and 
retention in tissues. Actinomycin D is not metabolized extensively (Calman et al., 
1980). It is metabolized by the liver and eliminated in the bile (up to 50 % ) and urine 
(6% to 31%) as unchanged drug (Fischer et al., 1997b). The common toxic side 
effects of actinomycin D including leukopenia, thrombocytopenia, nausea, vomiting 
and erythema (Fischer et aL, 1997b). 
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1.5.2.2. Cyclophosphamide (CY) 
^ 
Cyclophosphamide was flst reported in 1958 and has become the leading drug 
of the alkylating class in the clinical treatment of cancer. The clinical activity of 
cyclophosphamide is very broad, which explains its wide use. It is employed for 
treatment of leukemia, lymphoma, breast cancer, lung cancer, prostate cancer, and 
ovarian cancer. C Y is also immunosuppressive and is used in most conditioning 
regimens for bone transplantation (Black and Livingston, 1990; Mayumi et al., 1996). 
Cyclophosphamide itself is not cytotoxic. In the body, it is metabolized by 
hepatic microsomal enzymes to active metabolites which are released into the 
< 
systemic circulation. The mode of activation of cyclophosphamide is that the liver 
converts cyclophosphamide to a 4-hydroxy derivative which is in equilibrium with 
aldophosphamide. Neither of these compounds is cytotoxic, but aldophosphamide is 
cleaved to phosphoramide mustard and acrolein, both of which are toxic (Figure 1.2). 
The lower levels of enzymes in tumor cells that metabolize aldophosphamide to an 
inactive derivative may be the basis for the tumor selectivity of cyclophosphamide 
(Calman et al., 1980). 
The toxicities of cyclophosphamide are contributed by the end porducts on the 
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Figure 1.2. The metabolism of cyclophosphamide (Calman et al., 1980). 
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been implicated in denaturation of the cytochrome P450 family of isozymes (Gurtoo 
et al.，1981). Phosphoramide mustards probably involved in bladder toxicity, and it is 
known to be primarily responsible for cyclophosphamide‘s hematological toxicity. 
Other common toxicities are nausea, vomiting, versible alopecia (hair loss), bone 
marrow depression, gastrointestinal toxicity, and liver necrosis. Some rare toxicities 
include pulmonary toxicity and hemorrhagic carditis, which is observed occasionally 
after high dose of cyclophosphamide (Fischer et al., 1997b). 
1.5.2.3. Doxorubicin (Dox) 
Doxorubicin is the first anthracycline antibiotics in the clinic for 
< 
chemotherapy of malignant tumors. It is originally isolated from the fungus, 
Streptomyces peucetius. The drug has a planar anthraquinone ring attached to an 
amino sugar (Figure 1.3). Doxorubicin is widely used in the treatment of a variety of 
cancers in man. It is used in the treatment of wide variety of solid tumors, namely 
carcinoma of the breast, lung, thyroid, and ovary, soft tissue sarcomas, and many 
cancers of the blood. Doxorubicin exhibits multiple mechanisms of action in tumor 
cells and demonstrates a wide range of biochemical and pharmacological properties. 
It is known to intercalate into D N A and to inhibit topoisomerase II activity (Tewey et 
al., 1984; Chen et aL, 1984). It chelates transition metal ions, for example, iron and 
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copper. It also participates in oxidation-reduction systems in cells that generates free 
radicals (Handa and Sato, 1975). In addition, the compound interacts with cell 
* . . 
membranes and can modify membrane functions. These then impair the replication 
and growth of tumor cells. 
One of the major toxic effects of anthracycline free radical formation is the 
ability of doxorubicin to cause cardiomyopathy. It is known that heart tissue is able 
to activate doxorubicin to generate free radicals at multiple sites including cytosol, 
mitochondria, sarcoplasmic reticulum, and so on (Doroshow, 1986). Doxorubicin 
stimulates oxygen radical formation in the heart muscle, and, at the same time, it 
abrogates the major mechanism of peroxide removal by which the heart defends itself 
< 
against oxygen radicals. Other common toxicities include nausea, vomiting, 




AIM AND SCOPE OF THIS DISSERTATION 
Many studies have found that bioactive polysaccharides isolated from 
bacteria, fungi, and higher plant possess immunomodulatory and anti-tumor 
activities. The typical example was the polysaccharide fractions isolated from 
Pseudosterllria heterophylla which exhibited both mitogenic and anti-tumor activities 
(Wong, et a/., 1994). These polysaccharide fractions could markedly suppress the 
growth ofEAT cells in vivo (Wong, et al.，1994). However, these mitogenic fractions 
are heterogeneous arid multiple steps are required for purification. 
Capsular polysaccharides (CPS) isolated from Klebsiella pneumoniae have 
immunostimulatory and anti-tumor activities. Several of these polysaccharides, for 
example, serotype K1 and K24, have been studied. They are homogeneous and have 
well-defined structures. The culture of these serotype bacteria and the isolation of 
their CPS were reproducible in large quantity. Hence, K1 and K24 CPS are good 
candidates to be studied for their potential to be novel anti-tumor agents. 
In thesis project, the ability of K1 and K24 CPS in induction of TNF 
production from murine macrophages will be studied. Since the mechanism of how 
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CPS can activate the immune system of the host is unknown, the effect ofCPS on the 
, signal transduction pathway will be examined. The M A P K signaling pathways of 
macrophage will be used as the model for study. Also, the cytotoxic effect of 
different dosage of CPS on Ehrlich ascites tumor (EAT) in vivo and the effect on the 
survival of EAT-bearing mice will be examined. 
It has been reported that combination of immunotherapy with chemotherapy 
could augment the anti-tumor effect in experimental animals (Lasek et al., 1995; Das 
et al., 1989) and even in patients (Shiu et al., 1993). Therefore, the anti-tumor effect 
of combined treatment of immunotherapy using CPS, and chemotherapy using 
actinomycin D (Act D), cyclophosphamide (CY) and doxorubicin (Dox) will be 
< 
studied in vitro and in vivo. Finally, the effect of combined treatment of 
immunostimulatory CPS and the three chemotherapeutic drugs, actinomycin D， 





Materials and Methods 
3.1 Materials 
3.1.1. Animals 
Inbred female BALB/c (H-2^) mice aged 6-8 weeks were bred at the 
University Animal House of The Chinese University of Hong Kong under pathogen-
free condition. They were fed with animal diet (Chow 5001，Rodent Laboratory) and 
< 
tap water ad libitum. 
3.1.2. Klebsiella pneumoniae Serotype 1 and Serotype 24 
Klebsiella pneumoniae serotype 1 and serotype 24 were purchased from the 
International Escherichia coli and Klebsiella Center, Statens Seruminstitiute, 
Copenhagen, Denmark. The culture was obtained as slab culture. 
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3.1.3. Cell lines 
* , 
(I) Carcinoma 
1. E A T (Ehrlich ascites carcinoma) is an ascites derivative of a 
spontaneous murine mammary adenocarcinoma (teraploid subline Ny 
Klein Strain). 
2. WEHI-164, a methylcholanthrene-induced fibrosarcoma derived from 
BALB/c mice, was purchased from ATCC. 
All the above cell lines were maintained in continuous culture in RPMI 
medium supplemented with 10% FCS and 50 units/ml penicillin, 100 |ig/ml 
r 
streptomycin sulphate. Long term storage of the cell lines was achieved by 
cryopreservation in liquid nitrogen. 
3.1.4. Buffers, culture media and chemicals 
Culture broth for Klebsiella pneumoniae 
The culture broth was prepared by dissolving 2.00 g NaCl, 1.00 g K2HPO4, 
0.25 g MgS04.7H20, 0.50 g CaCO3, 30.00 g sucrose and 2.00 g B A C T O yeast 
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extract (Difco，USA) in 1 liter soluble distilled water and sterilized by autoclaving 
, atl21°Cfor30min. 
Agar medium for culturing Klebsiella pneumoniae 
The medium was prepared by adding 15.00 g B A C T O agar (Difco, USA) to 1 
litre culture broth mentioned above and sterilized by autoclaving at 121。C for 30 
min. The liquid agar broth was then poured into the petri dish of 90 m m diameter 
and solidified after 2 hours. 
Phosphate-buffered-saline fPBS) 
r 
PBS was prepared by dissolving 8.00 g NaCl, 0.20 g KC1, 0.20 g KH2PO4 and 
1.15 g Na2HPO4 (or 1.15 g Na2HP04*2H20 or 2.90 g Na2HP04. i2H2O) in one 
liter of double distilled water. The pH of the solution was adjusted to 7.4 before 
use. PBS was sterilized by autoclaving at 121。C for 30 min. 
Hank's buffered salt solution fHBSS) 
HBSS was prepared by dissolving 8.00 g NaCl, 0.40 g KCl，0.06 g KH2PO4, 0.35 
g NaHCO3, 0.12 g Na2HP04*12H20, 1.00 g D-glucose in one liter of double 
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distilled water. The solution was adjusted to pH 7.2 and sterilized by filtration 
. through a 0.22 ^ im millipore membrane filter. 
Culture medium 
RPMI 1640 medium (Sigma Chem Co., U S A with 25 m M HEPES) was used. 
The powder medium was dissolved in double distilled water and buffered with 25 
m M NaHCO3 according to manufacturer's specification. The RPMI solution was 
sterilized by filtration through a 0.22 ^ m millipore membrane filter. The plain 
medium was usually used for washing cells and stored at 4°C. During cell culture, 
the plain medium was supplemented with 50 units/ml penicillin, 100 i^g/ml 
streptomycin sulfate and 10% FCS (RPMI complete medium). 
Fetal calf serum fFCS) 
Fetal calf serum (Gibco, USA) was stored at -20。C as 50ml aliquots. Heat-
inactivated fetal calf serum FCS was used as a supplement to growth medium for cell 
culture in vitro and the final concentration would be 10%. 
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Penicillin-Streptomycin solution (PS) 
% . 
PS was bought from Gibco, USA. Stock solution (lOOx) containing 10,000 
units/ml of penicillin G, 10,000 ^ ig/ml of streptomycin sulfate was stored at -20°C at 
5ml aliquots. 5 ml of PS stock solution was added to 500 ml RPMI medium 
containing 10% FCS or plain RPMI medium. 
Normal saline 
Normal saline was prepared by dissolving 9.00 g NaCl in one litre double 
distilled water and sterilized by autoclaving at 12TC for 30 min. 
X 
Dye solutions 
1. Neutral red solution: 
Neutral red (0.5 g, Sigma Chem. Co., USA) was dissolved in 100 ml normal 
saline. The insoluble dye was filtered through Whatman No.l filter paper. 
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2. Trypan blue solution: 
Trypan blue (0.3g, Sigma Chem. Co., USA) was dissolved in 100ml sterilized 
PBS. The insoluble dye was filtered through Whatman No. 1 filter paper. 
Chemicals 
1. Lipopolysaccharide (LPS) 
LPS {E. coli serotype 026:B6, Sigma Chemical Co.) was dissolved in RPMI 
medium at 500 ^ ig/mL It was then stored as 250 ^il aliquot at -20。C until use. 
< 
2. Actinomycin D (Act D) 
Actinomycin D (Sigma Chemical Co.) was dissolved in D M S O as a stock 
solution of 500 [xg/ml and stored as 100 ^il aliquots at -20。C until use. 
3. Cyclophosphamide (CY) 
Cyclophosphamide (Sigma Chemical Co.) was dissolved in PBS as a stock 
solution of 20 mg/ml and stored at -20°C until use. 
4 Doxorubicin (Dox) 
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Doxorubicin (Sigma Chemical Co.) was dissolved in sterile double distilled 
、 water as a stock solution of 2.5mg/ml and stored at -20°C until use. 
Reagents used in phenol sulfuric acid method for carbohydrate determination 
1. Concentrated sulfuric acid 
2. 5% (v/v) phenol was prepared by diluting phenol with double distilled 
water. 
3. Dextran T-500 (standard was purchased from Pharmacia Biotech. Co., 
Sweden) and was dissolved in 0.15 M NaCl solution. The dextran 
standard (12.5 — lOO^ig/ml) was prepared by 2-fold serial dilution using < 
0.15MNaCl solution. 
Reagents used in Carbazole Reaction for uronic acid determination 
1. Carbazole (Reagent A) was prepared by dissolving 0.125 g carbazole in 
100 ml of absolute ethanol. It was stored in dark at 4°C. 
2. Borate sulfuric acid reagent (Reagent B) was prepared by dissolving 2.39 
g sodium tetraborate decahydrate in 250ml concentrated sulfuric acid. 
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3. Glucuronolactone standards (2.5 — 50 ^ g/ml) were prepared by dissolving 
, glucuronolactone in 0.15 M NaCl solution and serially diluted by 0.15 M 
NaCl solution. 
Reagents used in Bradford method for protein determination 
1. Bradford dye was prepared by dissolving 100 mg of Coomassie brilliant 
blue G-250 in 50 ml of 95 % ethanol. 100ml of concentrated phosphoric 
acid was added. Distilled water was added to a final volume of 200 ml. It 
was stored in dark at 4°C. 
2. Bovine serum albumin (BSA) was purchased from Sigma Co., USA. 
r 
BSA standards (2.5 - 50 mg/ml) were prepared by dissolving in 0.15 M 
NaCl solution and serially diluted by 0.15 M NaCl. 
Solution for Westem Analysis 
Lysis Buffer 
Lysis buffer was freshly prepared by mixing the stock solutions as follows and 
stored on ice before use. 
49 
Stock solutions Volume Final Concentration  
l X P B S ^ 
, 2.1 mg/ml Aprotinin 100 jul 21 ^ ig/ml Aprotinin 
1 mg/ml Leupeptin 5 ^il 0.5 |ug/ml Leupeptin 
4.9 M MgCl2 10 ^il 4.9 m M MgCl2 
100 m M Sodium Meta-Vanadate 100 ^il 1 m M Sodium Meta-Vanadate 
10% Triton X-100 1 ml 1 % Triton X-100 
100 m M PMSF lQQ ^ 1 1 m M PMSF  
Total volume 10.315 ml 
PBS containing 1 m M Meta-vanadate 
PBS containing l m M Meta-vanadate was freshly prepared by mixing 100 ml 
PBS with 1 ml 100 m M Meta-vanadate and stored on ice before use. 
2X SDS Sample Buffer with Bromophenol Blue and Mercaptoethanol (pH 6.8) 
Antibodies 
Polyclonal rabbit anti-active ERKl/2, anti-active JNK 1/2 and anti-active p38 
were from Promega. Polyclonal rabbit anti-total JNK1, anti-total p38 were from 
Santa Cruz. Monoclonal anti-mouse total ERK1 and polyclonal anti-rabbit total 




3.2.1. Extraction, Purification and Characterization of K1 and K24 Capsular 
Polysaccharides (CPS) from Klebsiella pneumoniae 
3.2.1.1. Extraction and Purification of K1 and K24 Klebsiella Capsular 
Polysaccharides (CPS) 
The procedure for extraction and purification of capsular polysaccharide was 
shown in Figure 3.1. The Klebsiella pneumoniae was cultured on agar plates and 
grew at 37°C for 2 days. The bacteria in mucoid form was harvested and killed with 
1.0 % phenol in normal saline. The bacteria was centrifuged at 19,000 x g for 3h by 
high-speed centrifligation and the cell-free supernatant was then dialyzed against 
distilled water ovemight using dialysis tubing with membrane pore size of 3,500 
(Spectra/POR 4). The sample was then lyophilized for 3 days. The lyophilized 
powder, which was designated as the crude extract, was subjected to Cetavlon 
precipitation. Briefly, the crude extract was dissolved in distilled water (1.00 % w/v) 
and 5 % Cetavlon (A^ -cetyl-A^ ,A^ ,iV-trimethyl-ammonium bromide, Sigma) was added 
slowly to the dissolved extract in 1:1 w/w ratio. After centrifugation at 800 x g for 5 
min, the precipitate of the extract could be obtained and the supematant was 
discarded. Minimum volume of 4 M NaCl solution was then added to dissolve the 
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pellet of extract with continuous stirring. The dissolved extract was then slowly 
, added to large volume (e.g. 500 ml) of 95% ethanol with continuous stirring using 
glass rod. Silk-like product could be obtained around the glass rod. The product was 
again dissolved in minimum amount of distilled water and then poured on to 95 % 
ethanol to obtain the polysaccharide. The above procedure was repeated twice. The 
silk-like product was then blotted dry and dissolved in distilled water, followed by 
dialysis against distilled water at 4。C for 48 h. The sample was lyophilized for 3 days 
and was designated as capsular polysaccharide antigen. 
3.2.1.2. Gel filtration o f K l and K24 Klebsiella Capsular Polysaccharides 
X 
Capsular polysaccharides were applied on to a Sepharose CL-2B (Pharmacia ) 
column (2.6 x 57 cm) and eluted with 0.15 M NaCl. Fractions of 4.4 ml were 
collected at a flow rate of 17.6 mVh. The relative amount of carbohydrate in each 
fraction was determined by phenol sulfuric acid method (O.D.485) (Dubois et al., 
1956). 
3.2.1.3. Characterization o fKl and K24 Capsular Polysaccharides 
Protein content was determined by the Bradford method using bovine serum 
albumin (BSA) as a standard (Bradford, 1976). Carbohydrate content was determined 
by the phenol sulfuric acid method (Dubois et al., 1956) while uronic acid content 
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was determined by the carbazole method (Bitter and Muir, 1962). Results were 
, expressed as mean 土 standard error (S.D.) of triplicate determinations. 
Phenol sulfuric acid method for carbohydrate determination 
The sample (0.2 ml) was added to a test tube, and 0.2 ml 5 % phenol was 
added and mixed well. Then 1 ml concentrated sulfuric acid was added steadily to the 
solution. The mixture was allowed to stand for 30 min. The absorbance at 485 nm of 
each sample was measured. 
Bradford method for protein determination 
r 
The sample (0,1 ml) was added to a test tube, and 5 ml of the diluted 
Bradford's reagent was added and mixed immediately. The sample was allowed to 
stand for 10-30 min. The absorbance at 595 nm of each sample was measured. 
Carbazole Reaction for uronic acid determination 
1.5 ml Reagent B was added to a test tube placed into ice bath. The sample 
(0.25 ml) was added slowly in the top of the Reagent B. 50 jil Reagent B was added 
and mixed well. The sample was boiled (100%) in water bath for 15 min. After 
cooling down, the absorbance at 525 nm of each sample was measured. 
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Culture of Klebsiella pneumoniae on agar medium at 3TC for 2 days 
’ ,, 
V 
Harvest and kill the Klebsiella mucoid colonies with 1% phenol in normal saline 
> • w 
Centrifuge at 19,000 x g for 3 hr at 4 T 
>» • 
w 
Lyophilize for 3 days to obtain the crude extract 
> f V 
Dissolve the crude extract in double distilled water (1% w/v) 
> • V 
Dialyse the cell-free supernatant against double distilled water ovemight 
> • w 
Add 5 % Cetavlon in 1:1 (w/w) ratio 
> • 
V 
Centrifuge at 3000 x g for 15 min to obtain a pellet 
> • 
w 
Dissolve the pellet in 4 M NaCl with continuous stirring 
v^  
Slowly pour the dissolved extract into 95 % ethanol 
& obtain the silk-like product by stirring with a glass rod 
> • V 
Blot the silk-like product dry & redissolve it in distilled water with 
continuous stirring, add slowly to 95 % ethanol (2 x) 
> • w 
Blot the silk-like product dry & dissolve it in distilled water 
> • w 
Dialyse against distilled water at 4。C for at least 3 days 
v 
Lyophilize for 3 days to get dry sample 
、• 
w 
Obtain purified Klebsiella capsular polysaccharides 
Figure 3.1: A flow chart showing the extraction and purification procedures ofcapsuIar 
Polysaccharides from Klebsiella pneumoniae. 
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3.2.3. Assay for Macrophage Activating Activities of Klebsiella Capsular 
， Polysaccharides 
3.2.3.1. Tumour Necrosis Factor-a (TNF-a) Production by Peritoneal 
Macrophages 
On day 0，BALB/c mice were individually peritoneally injected with 1ml 3% 
Brewer thioglycollate. On day 3, the mice were killed and the abdomen of each 
mouse was wetted with 70% ethanol to sterilize the area. A midline incision was 
made with sterile scissors. The abdominal skin was retracted with forceps to expose 
r 
the intact peritoneal wall. Peritoneal fluid was harvested by HBSS and was dispensed 
to 50-ml centrifuge tube on ice. The cell was centrifuged at 2,000 rpm for 3 min. 
Half-isotonic PBS was added to lyse the contaminating red blood cells. The cells 
were centrifuged at 2,000 rpm for 3 min. The lysing process was repeated (about 4 
times) until most of the red blood cells were lysed. The cells were resuspended in 
RPMI-10% FCS. The cells were placed in flask to grow for 3-4 hours then remove 
the non-adherent contaminating cells by replacing with fresh medium. Macrophages 
were grown in flask over night. Macrophages were scraped from flasks and 
resuspended in complete RPMI medium at 3 x 10^  cells/ml. 0.1 ml peritoneal 
macrophage suspension was added into each well of a flat-bottomed 96-well 
microtiter plate. The cells were then incubated with different concentrations of CPS 
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(K1 or K24) antigen or 1 ^ ig/ml of LPS in vitro at 2>TC. 100 ^ 1 of cell free culture 
, supernatant was collected 24 hr later and TNF activity of the supematant was 
determined by ELISA kit using recombinant murine TNF-a (rmTNF-a) as standard. 
3.2.3.2. Effect of Capsular Polysaccharides on the activities of MAPK family in 
murine macrophages 
Protein sample preparation of murine macrophages 
On day 0, BALB/c mice were individually peritoneally injected with 1ml 3% 
Brewer thioglycollate. On day 3，the mice were killed and the abdomen of each 
mouse was wetted with 70% ethanol to sterilize the area. A midline incision was 
X 
made with sterile scissors. The abdominal skin was retracted with forceps to expose 
the intact peritoneal wall. Peritoneal fluid was harvested by HBSS and was dispensed 
to 50-ml centrifuge tube on ice. The cell was centrifuged at 2000 rpm for 3 min. 
Half-isotonic PBS was added to lyse the contaminating red blood cells. The cells 
were centrifuged at 2000 rpm for 3 min. The lysing process was repeated (about 4 
times) until most of the red blood cells were lysed. The cells were resuspended in 
RPMI-10% FCS. The cells were placed in flask to grow for 3-4 hours then remove 
the non-adherent comtaminating cells by replacing with fresh medium. Peritoneal 
macrophages were grown in flask over night. Macrophages were scraped from flasks 
and 3 x 10^  cells were seeded onto 60 m m dish for each condition (70% confluence 
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with some dead cells flowing). Macrophages were allowed to adhere for 3-4 hours. 
, The medium was replaced with 2850 ^il fresh medium. 50 ^ il/ml (i.e. 150 ^ 1) ofCPS 
were added to the culture dish at 0，5，10, 20, 30 and 60 minutes at 37。C. Reaction 
was stopped by suction. The plates were washed 3 times with filtered PBS-
metavanade. The cells were lysed by 50 ^ il cold freshly prepared lysis buffer and 
cells were-scraped off the plate by scraper (non-sterile). The cells were placed on ice 
for 10 minutes with mixing and centrifuged at 14000 rpm at 4°C for 7 minutes. After 
centrifugation, protein content in the supernatant was quantitated using the Micro 
B C A Protein Assay Kit (Pierce Chemical Co., Rockford, IL). The volume of the 
supernatant was measured and transferred to a screw-cap microcentrifuge tube. The 
supernatant was diluted with 2X sodium dodecyl sulphate (SDS) sample buffer (125 
r 
m M Tris-2.2 M glycerol-1.42 M P-mercaptoethanol-160 m M sodium dodecyl 
sulphate - 10 mg/L bromophenol blue, pH 6.8)，boiled for 10 min and stored at —70°C 
until use. 
SDS-polyacrylamide gel electrophoresis ofprotein 
The gel box was set up using 1 m m spacers according to instruction. Lower 
gel of 8% (for protein size 49 to 194 kDa) or 12% (for protein size 21.9 tol42.9 kDa) 
acrylamide lower gel solution was made according to the following table: 
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, Amount needed for 2 small geh 8% 12% 
Double-distilled Water 7.63 ml — 5.5 ml 
30% Acrylamide 4.27 ml 6.4 ml 
(Sigma Chemical Co., St. Louis, M O ) 
4X Lower Gel Buffer 4 ml 一 4 ml 一 
T E M E D (Gibco, USA) 18.6 ^ 1 18.6|ul 
10% Ammonium Persulphate 80 ^ 1 80 p,l 
(Sigma Chemical Co., St. Louis, M O ) 
— Total Volume (-5ml/gel) 15.9986 ml 15.9986 ml 
Gel solution was poured to 2.2 cm from top of glass with a 1 ml pipette. The top was 
immediately overlayed with 1 ml 70% ethanol and allowed to set for at least for 30 
min. 
4.5 % Acrylamide upper stacking gel was made as follows: 
Amount needed for 2 small gels 4.5 % 
Double-distilled Water 4.8 ml 
~3Q% Acrylamide (Sigma Chemical Co.7^Louis, M Q ) 1.2 ml 
4X Lower Gel Buffer 2.0 ml 
T E M E D (Gibco, USA) “ 10.6 ml — 
10% Ammonium Persulphate 60 ^ 1 
(Sigma Chemical Co., St. Louis, M O ) 
Total Volume 8.07 ml 
70 % ethanol was poured off from the top of the gel and washed twice with double 
distilled water was removed by kimwipes. Gel was poured to top of lower gel with a 
1 ml pipette. 10-wells comb was inserted. The gel was allowed to set for 30 min. 
The gel chamber was assembled according to manufacturer's instruction. Upper 
reservoir was filled with about 115 ml and lower reservoir with 200 ml IX SDS 
Running Buffer. The comb was carefully removed. 
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. Sample Loading and Gel Running 
The protein concentration of sample was adjusted to 25 p,g protein in 15 |al 
with IX Sample Buffer. 5 ^ il Prestained Molecular Weight Standards (Bio-Rad) in 
10 ^il IX Sample Buffer of 15 ^ 1 sample was loaded to each well. Gels were run at 
constant voltage of 200V for 45 min. 
Electroblotting 
Thick blotter papers (Bio-Rad) and Immobilon-P membranes (Millipore, 
Bedford, M A ) of size similar to that of the gel were cut. Immobilon-P membrane 
was wet for 2 sec in )00% methanol in square petri dish and placed in E-blot Transfer 
Buffer for 5 min. After running, the gels were rinsed in E-blot Transfer Buffer once. 
One piece of blotter paper was soaked in E-blot Transfer Buffer and placed onto the 
platinum anode of the semi-dry transfer unit (Bio-Rad). The surface of the blotter 
paper was rolled over by a test tube to exclude all air bubbles. 
The equilibrated membrane was carefully placed on the blotter paper and 
rolled out air bubbles. The gel was placed on the top of the membrane with 
orientation same as the gel when loading (i.e. first lane at the left-hand side) and 
rolled out all air bubbles. One piece of blotter paper was soaked in E-blot Transfer 
Buffer and place onto the gel and rolled out all air bubbles. The same steps were 
repeated for other gels. The cathode was carefully placed onto the stack, then the 
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safety cover was placed. The transfer was carried for 30 min at 15V, limited to 
. 0.5Amp was for 1 to 2 gels, lA for 4 gels. The membrane was removed from semi-
dry transfer unit (Bio-Rad) and the membrane was air dried at room temperature. 
The membrane was kept between two pieces of clean paper or in an envelope for later 
use, or directly used for antibody probing and blot developing. 
Antibody Probing 
The membranes were immersed in methanol of 10 sec then into IX PBS for 2 
sec. The membranes were incubated in 5 % non-fat dry milk at 4°C ovemight for 
blocking the membranes. The membranes were rinsed three times with TBS 
containimg 0.1 % Tween 20 (TBS-T). The membranes were rocked in TBS-T for 
r 
lOmin and the TBS-T was drained. Rinsing and draining was repeated once. 
Primary antibody was diluted in TBS-T, and 10 |il of 10 % thimerosal was added as 
preservative for every 3 ml TBS-T containing primary antibody. The primary 
antibody was added to the membrane and rocked in a square petri dish for 2 h at room 
temperature. The membrane was rocked by hand about every 30 min to prevent the 
membrane stick to the bottom of the dish, (The used primary Ab can be stored at 4°C 
in a tube and re-used later for 1-2 more times.) The membranes were rinsed three 
times with TBS-T. The membranes were rocked in TBS-T for 10 min and the TBS-T 
was drained. Rinsing and draining was repeated once. Horseradish peroxidase-
conjugated secondary antibody-sheep anti-mouse IgG (Amersham, Arlington 
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Heights, IL) or donkey anti-rabbit IgG (Amersham，Arlington Heights, IL), 
, depending on the origin of the primary antibody, was diluted at 1:20,000 (0.25 n,l 
Ab/5 ml TBS-T) in TBS-T. Each membrane was rocked in 5 ml diluted secondary 
antibody for 1 h at room temperature. The membrane was rinsed three times with 
TBS-T. The membranes were rocked in TBS-T for 10 min and the TBS-T was 
drained. Rinsing and draining was repeated once. The membrane was ready for 
detection using ECL Chemiluminescence System (Amersham Arlington Heights, IL). 
Detection (by ECL Western Blotting Detection Reagents, Amersham) 
Equal volumes of detection reagents 1 & 2 of the ECL (Enhanced 
chemiluminescence) reagent kit were mixed (4 ml reagent mixture for each 
r 
membrane). Each membrane was placed on a square petri dish with protein side up. 
The detection reagent mixture was added to the protein side of the membrane so that 
the reagent was held by surface tension on the surface of the membrane. The 
membrane was incubated exactly 1 min at room temperature without agitation. 
Excess detection reagent was drained off by holding the edge of the membrane 
vertically against tissue paper. The Membrane was placed on a saran-wrap with 
protein side down and wrapped on the back. Any air pockets were gently smoothed 
out. The membrane was placed with protein side up in the film cassette. In dark 
room，a sheet of autoradiography film (X-AR film，Kodak) was carefully placed on 
top ofthe membranes, the cassette was closed and exposed for 15 sec to 1 min. The 
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exposed film was removed and developed in an automatic film processor. An 
, unexposed film was immediately replaced and expose for about 5 min. 
< 
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3.2.4. Assay for Anti-Tumor Activities ofKlebsiella Capsular Polysaccharides 
X 3.2.4.1. Assay of in vivo Suppression of EAT growth by K1 and K24 Capsular 
Polysaccharides 
To study the effect of capsular polysaccharides on the growth of E A T 
carcinoma in vivo, BALB/c mice in groups of five were injected i.p. with 10^ E A T 
cells on day 0. CPS was then injected i.p. for 4 consecutive days (days 5 - 8) whereas 
control mice were injected with an equal volume of PBS. On day 9, E A T cells in the 
peritoneal cavity of each mouse were harvested by exhaustive drainage. Cells 
recovered were counted with a hemocytometer by the trypan blue exclusion method 
(Philip, 1973). The % suppression of each group was calculated as follows: 
Suppression (%) = [ ( C e l l c o n t r o i — Cell cps)丨 C e l l c o m r o i ] x 100% 
where Cell controi = the mean number of E A T cells present in the peritoneal cavity of 
the mice of the control group 
Cell CPS = the mean number of E A T cells present in the peritoneal cavity of the mice 
of the CPS-treated group 
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3.2.4.2. Assay ofthe Effect ofCPS on the Survival ofEAT-Bearing Mice 
To study the effect of CPS on the survival of EAT-bearing mice, BALB/c 
mice in group of 20 were injected i.p. with 10^ EAT cells on day 0. CPS antigen or 
PBS as control was then injected i.p. according to different regimens. 
Day Regimen A (4-day treatment) Regimen B (Continuous treatment) 
" ^ 10^  EAT cells/0.2 ml PBS/mouse 10^  E AT cells/0.2 ml PBS/mouse 
5 20 jig K1 CPS or 40 ^ ig K24 CPS /0.2 20 [xg K1 CPS or 40 ^ ig K24 CPS /0.2~ 
ml PBS/mouse/day Starts ml PBS/mouse/day Starts 
~~9 CPS Injection stop ‘ 
30 End of the experiment CPS Injection stop “ 
(End of the experiment) 
X  
For the control group of each regimen, 0.2 ml PBS was injected i.p. to each mouse of 
the group. The mice in each group were observed daily for their survival. The 
mortality pattem of the EAT-bearing mice was determined and presented in term of 
survival rate (%). 
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3.2.5. Assay for Anti-Tumor Activities of Combined Treatment of Klebsiella 
, Capsular Polysaccharides and Chemotherapeutic Drugs (Actinomycin D 
(Act D), Cyclophosphamide (CY) and Doxorubicin (Dox) 
3.2.5.1. Assay of the Cytotoxic Effect of Chemotherapeutic Drugs: Actinomycin 
D (Act D), Cyclophosphamide (CY) and Doxorubicin (Dox), on WEHI-
164 cell line 
To study the cytotoxic effect of chemotherapeutic drugs, WEHI-164 cells, 
with the cell concentration of 1 xlO^ cells/well, were seeded in 200 |al RPMI 
complete medium in 96-well plate. After 24 hours, the original culture medium were 
removed and different concentrations of the chemotherapeutic drugs (Act D, C Y & 
Dox),which dissolved in 200 i^l culture rnedium, were added to each well. The 
WEHI-164 cells were cultured with these drugs at 37°C for 24 hours. The cell 
viability was measured by neutral red assay. The % cytotoxicities of the drugs were 
calculated as follows: 
Cytotoxicity (%) 二 [l-(O.D.(Drug)/O.D.(c�ntr�l))] X 100 % 
where O.D.(Drug)= the mean value of Aborbance at 540 nm of drug-treated cells 
O.D.(Controi) = the mean value of Aborbance at 540 nm of the cells which only 
cultured with culture medium 
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Results were expressed as the arithmetic mean + S.D. of five samples. 
•*. 
3.2.5.2. Assay of the Combined Treatment of the CPS and Chemotherapeutic 
Drugs (Act D, CY and Dox) on WEHI-164 cell line in vitro 
To. study the cytotoxic effect of combined treatment of the C A and 
chemotherapeutic drugs (Act D, C Y and Dox) on WEHI-164 cells, WEHI-164 cells, 
with the cell concentration of 1 xlO^ cells/well, were seeded in 200 ^1 RPMI 
complete medium in 96-well plate. After 24 hours, the original culture medium were 
removed and different combinations of drugs (as shown in the table below), which 
dissolved in 200 ^ 1 culture medium, were added to each well. 
< 
K1 and Chemotherapeutic drugs K24 and Chemotherapeutic drugs 
Control Kl Control ^1 
Act D Kl + Act D ActD Kl + Act D 
CT K l + C Y CT K l + C Y 
Dox Kl + Dox D ^ Kl + Dox 
The WEHI-164 cells were cultured with these drugs at 37°C for 24 hours. The cell 
viability was measured by neutral red assay. The % cytotoxicities ofthe drugs were 
calculated as follows: 
Cytotoxicity (%) = [l-(O.D.(Drug)/O.D.(co_i))] x 100 % 
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where O.D.(Drug)= the mean value of Aborbance at 540 nm of chemotherapeutic drug-
treated cells 
O.D.(Controi) = the mean value of Aborbance at 540 nm of the cells which only 
cultured with culture medium 
3.2.5.3. Assay for Anti-Tumor Effect of Chemotherapeutic Drugs (Act D, CY 
and Dox) on EAT-bearing Mice in vivo 
BALB/c mice in group of five were injected i.p. with 10^ E A T cells on day 0. 
Chemotherapeutic drugs with different concentrations were then injected i.p. at day 5 
r 
whereas control mice were injected with an equal volume of PBS. On day 9, EAT 
cells in the peritoneal cavity of each mouse were harvested by exhaustive drainage. 
Cells recovered were counted with a hemocytometer by the trypan blue exclusion 
method. Results were expressed as mean 土 S.D. 
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3.2.5.4. Assay of the Combined Treatment of the CPS and Chemotherapeutic 
Drugs (Act D, CY and Dox) on EAT-bearing Mice in vivo 
%. 
BALB/c mice in group of five were injected i.p. with 10^ E A T cells on day 0. 
C A antigen was then injected i.p. for 4 consecutive days (days 5 - 8) whereas control 
mice were injected with an equal volume ofPBS. However, chemotherapeutic drugs 
were injected i.p. to mice only on day 5 (one dose). The tables below show the drugs 
and the day of injection. 
Combined Treatment o fKl and Act D 
Day Control m ActD Kl+Act D 
0 10' EAT cells/0.2 ml PBS/mouse 
5 ~~0.2 ml PBS + ~ ~ 0.2mlKl+ 0.2 ml PBS + ~ ~ 0.2 ml K1 + ~~~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Act D 0.2 ml Act D 
6 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
7 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
8 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
9 Peritoneal EAT cell harvesting 
68 
Combined Treatment of K1 and CY 
, D ^ Control Jo CT Kl+CY 
0 i0'EATcells/0'2mlPBS/mouse 
5 0.2 ml PBS + ~ ~ 0.2mlKl+ 0.2mlPBS+ 0.2 ml K1 + ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml C Y 0.2 ml C Y 
6 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
7 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
8 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
9 Peritoneal EAT cell harvesting 
Combined Treatment of K1 and Dox 
D ^ Control S i D ^ Kl+Dox 
0 10'EATcells/0.2mlPBS/mouse 
5 0.2 ml PBS + ~ ~ 0.2mlKl+ 0.2 ml PBS + 0.2 ml K1 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Dox 0.2 ml Dox 
6 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
7 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
8 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 mlKl 
9 Peritoneal EAT cell harvesting 
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Combined Treatment ofK24 and Act D 
� Day Control K ^ ActD Kl+Act D 
0 10'EATcells/0.2mlPBS/mouse 
5 ~~~0.2 ml PBS + ~ ~ 0.2mlK24+ 0.2mlPBS+ ~~0.2 ml K24 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Act D 0.2 ml Act D 
6 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
7 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
8 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24~~" 
9 Peritoneal E A T cell harvesting 
Combined Treatment o fKl and CY 
Day Control ^ 4 CT Kl+CY 
0 10'EATcells/0.2mlPBS/mouse 
5 ~~0.2 ml PBS + ~ 0.2mlKl+ 0.2 ml PBS + ~~0.2 ml K24 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml C Y 0.2 ml C Y 
6 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K 2 4 ~ ~ 
7 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K 2 4 ~ 
8 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K 2 4 ~ ~ 
9 Peritoneal EAT cell harvesting 
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Combined Treatment of K1 and Dox 
D ^ Control ^ D ^ K1 + Dox 
‘ 0 10' EAT cells/0.2 ml PBS/mouse 
5 0.2 ml PBS + ~ ~ 0.2mlK24+ 0.2mlPBS+ ~~0.2 ml K24 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Dox 0.2 ml Dox 
6 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
7 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
8~~~: 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
9 Peritoneal EAT cell harvesting 
On day 9, EAT cells in the peritoneal cavity of each mouse were harvested by 
exhaustive drainage. Cells recovered were counted with a hemocytometer by the 
trypan blue exclusion method. Results were expressed as mean 土 S.D. 
X 
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3.2.5.5. Assay of the Combined Treatment of the CPS and Chemotherapeutic 
Drugs (Act D，CY and Dox) on the Survival ofEAT-bearing Mice in vivo 
， 
BALB/c mice in group of twenty were injected i.p. with 10^ E A T cells on day 
0. C A antigen was then injected i.p. for 4 consecutive days (days 5 - 8) or 26 
consecutive days (days 5 - 30) whereas control mice were injected with an equal 
volume ofPBS. However, chemotherapeutic drugs were injected i.p. to mice only on 
day 5 (one dose). The tables below show the drugs and the day ofinjection. 
Combined Treatment of K1 and Act D 
Day Control m ActD Kl+Act D 
0 10'EATcells/0.2mlPBS/mouse 
5 ~~0.2 ml PBS + ~~~ 0.2mlKl+ 0.2mlPBS+ ~~0.2 ml K1 + ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Act D 0.2 ml ActD 
6 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
7 0,2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
8 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
9 -30 10 mice of each group (Stop Injection) & 
10 mice ofeach group (Continue Injection) 
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Combined Treatment o fKl and CY 
D ^ Control m CT Kl+CY 
^ 
0 10' EAT cells/0.2 ml PBS/mouse 
5 0.2 ml PBS + ~ ~ 0.2mlKl+ 0.2mlPBS+ ~~0.2 ml K1 + ~~~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml C Y 0.2 ml C Y 
6 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
7 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
8 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
9 10 mice of each group (Stop Injection) & 
10 mice of each group (Continue Injection) 
Combined Treatment o fKl and Dox 
Day Control l a D ^ Kl+Dox 
0 : 10' EAT cells/0.2 ml PBS/mouse 
5 ~~0.2 ml PBS + ~ ~ 0.2mlKl+ 0.2 ml PBS + ~~0.2 ml K1 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Dox 0.2 ml Dox 
6 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
7 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
8 0.2 ml PBS 0.2 ml K1 0.2 ml PBS 0.2 ml K1 
9 10 mice of each group (Stop Injection) & 
10 mice ofeach group (Continue Injection) 
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Combined Treatment ofK24 and Act D 
, 5 ^ Control ^ 4 ActD Kl+Act D 
0 10'EATcells/0.2mlPBS/mouse 
5 0.2 ml PBS + ~ ~ 0.2mlK24+ 0.2mlPBS+ ~~0.2 ml K24 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Act D 0.2 ml Act D 
6 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
7 0.2 ml PBS 0,2 ml K24 0.2 ml PBS 0.2 ml K24 
8 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K 2 4 ~ 
9 10 mice of each group (Stop Injection) & 
10 mice of each group (Continue Injection) 
Combined Treatment o fKl and CY 
D ^ Control i ^ CT Kl+CY 
0 < 10^  EAT cells/0.2 ml PBS/mouse 
5 ~~0.2 ml PBS + ~ ~ 0.2 ml Kl + 0.2 ml PBS + ~~~0.2 ml K24 + ~~" 
0.2 ml PBS 0.2 ml PBS 0.2 ml C Y 0.2 ml C Y 
6 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
7 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24~~~ 
8 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K 2 4 ~ 
9 10 mice of each group (Stop Injection) & 
10 mice of each group (Continue Injection) 
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Combined Treatment o f Kl and Dox 
, D ^ Control K ^ D ^ K1 + Dox 
0 10' EAT cells/0.2 ml PBS/mouse 
5 0.2 ml PBS + ~ ~ 0.2mlK24+ 0.2mlPBS+ ~~0.2 ml K24 + ~ ~ 
0.2 ml PBS 0.2 ml PBS 0.2 ml Dox 0.2 ml Dox 
6 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
7 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K24 
8 0.2 ml PBS 0.2 ml K24 0.2 ml PBS 0.2 ml K 2 4 ~ ~ 
9 10 mice of each group (Stop Injection) & 
10 mice of each group (Continue Injection) 
The mice in each group were observed daily for their survival. The mortality pattem 





EXTRACTION, PURIFICATION & CHARACTERIZATION OF 
KLEBSIELLA K1 & K24 CAPSULAR POLYSACCHARIDES 
4.1. Extraction and Purification of K1 and K24 Capsular Polysaccharides from 
Klebsiella pneumoniae Serotype 1 and Serotype 24 
Klebsiella pneumoniae serotype 1 and serotype 24 were grown separately for two 
days at 37°C. The bacteria were harvested and killed with 1 % phenol in normal 
r 
saline. The crude extract containing K1 and K24 capsular polysaccharides were 
obtained by ultracentrifugation, in which the cell-free supematants were dialyzed in 
double-distilled water and then lyophilized. K1 and K24 antigen were then purified 
from the crude polysaccharide fraction by coprecipitation with a quaternary 
ammonium salt (Cetavlon) and followed by alcohol precipitation. The yields of 
purified K1 and K24 antigens from the crude polysaccharide fractions were found to 
be 50.21 % and 62.10 % respectively. 
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4.2. Gel Filtration Chromatography o f K l and K24 Capsular Polysaccharides 
^ , 
Since the immunogenicity of bacterial capsular polysaccharides were found to be 
dependent on their molecular weight (Gotschlich et al.，1972 & Wong et al., 1977), 
therefore, the molecular weights of K1 and K24 was estimated by gel filtration 
chromatography on a Sepharose CL-2B column. K1 showed a single peak in the 
elution profile and retained in the gel, that is，with molecular weight lower than 5 
xl06 (Figure 4.1b). Hence, K1 CPS might be considered to be homogeneous in 
nature. Also, K1 was totally eluted out before the dextran of molecular weight of 2 
xl06 using Sepharose CL-4B (data not shown). Therefore, the molecular weight of 
K1 CPS was estimated to be between of2 xlO^ and 5 xlO^ 
On the other hand, K24 CPS was eluted as a single peak near the void volume 
(Figure 4.1c) which was determined by gel filtration of dextran (average molecular 
weight = 5 - 40 x 10^) over the column (Figure 4.1a). Thus the estimated molecular 
weight ofK24 CPS was found to be slightly less than 5 x 10^ 
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Figure 4.1a. Gel Filtration of Dextran for Determination of Void Volume. 
Dextran (Average M.W. = 5 — 40 x 10^) (2.0 mg) was dissolved in 3 ml 0.15 M NaCl 
and applied onto a Sepharose CL-2B column (2.6 cm x 57 cm). Fractions were 
eluted with 0.15 M NaCl. Fractions of 4.4 ml were obtained at a flow rate of 17.6 
ml/h. Fractions 21-35 were collected as the dextran. The relative amount of 
carbohydrate in each fraction was determined by the phenol sulfuric acid method 
(Absorbance at 490 nm). Void volume = 154 ml 
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Figure 4.1b. Gel Filtration of K1 Capsular Polysaccharide. K1 CPS (2.0 mg) 
was dissolved in 4 ml 0.15 M NaCl and applied onto a Sepharose CL-2B column (2.6 
cm X 57 cm). Fractions were eluted with 0.15 M NaCl. Fractions of4.4 ml were 
r 
obtained at a flow rate of 17.6 ml/h. Fractions 49 to 68 were collected as the K1 
capsular polysaccharide. The relative amount of carbohydrate in each fraction was 
determined by the phenol sulfuric acid method (Absorbance at 490 nm). Void 
volume = 154 ml (determined from the dextran elution profile in Figure 4.1a); 
elution volume = 299.2 ml. 
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Figure 4.1c. Gel Filtration ofK24 Capsular Polysaccharide. K24 CPS (2.0 mg) 
was dissolved in 4 ml 0.15 M NaCl and applied onto a Sepharose CL-2B column (2.6 
cm X 57 cm). Fractions were eluted with 0.15 M NaCl. Fractions of 4.4 ml were 
obtained at a flow rate of 17.6 ml/h. Fractions 22 to 61 were collected as the K24 
capsular polysaccharide. The relative amount of carbohydrate in each fraction was 
determined by the phenol sulfuric acid method (Absorbance at 490 nm). Void 
volume = 154 ml (determined from the dextran elution profile in Figure 4.1a); 
elution volume = 268 ml. 
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4.3. Characterization o f K l and K24 Capsular Polysaccharides 
^ . 
The carbohydrate, protein and uronic acid contents of K1 and K24 capsular 
antigens were determined and shown in Table 4.1. K1 antigen was found to contain 
mainly carbohydrate (75.1%) of which 30.2% (w/w) is uronic acid. Similarly, K24 
antigen was found to contain mainly carbohydrate (82.0%) ofwhich 20.2% (w/w) is 
uronic acid. Only trace amount of protein were detectable in both K1 (0.7%) and 
K24 (0.1%) antigens. 
X 
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Table 4.1: Composition ofKl and K24 Capsular Polysaccharides 
^ . 
Components Dry weight (%) 
K1 ^ 
Carbohydrate 44.9 61.8 
Protein 0.7 0.1 
Uronic acid 30.2 20.2 
Dextran T500 (M.W. 519,000) and D-glucurono-6,3-lactone were used as standards 
for the assays of carbohydrate and uronic acid, respectively. Carbohydrate content 
was determined by phenol sulphuric acid method. Protein content was determined by 
Bradford method. Uronic acid content was determined by carbazole reaction. 




EFFECT OF THE K1 & K24 CAPSULAR POLYSACCHARIDES 
ON THE MACROPHAGE ACTIVITIES 
5.1. Effect o f K l and K24 Capsular Polysaccharides on the in vitro induction of 
TNF-a Production of Murine Peritoneal Macrophages 
TNFs are well-known cytokines that mediate cytotoxic/cytocidal activities 
against tumors (Bonta and Ben-Efraim, 1993), and participate in various immune 
< 
regulations (Kehrl et al., 1987 & Scheurich et al., 1987). As shown in Fig. 5.2a and 
5.2b，peritoneal macrophages incubated for 24 hours with increasing concentrations 
of K1 and K24 CPS, ranging from 0.78725 to 50 |igAnl, had resulted in a dose-
dependent release ofTNF-a, as measured by the TNF-a ELISA kit in both cases. K1 
and K24 with the concentration of 50 jag/ml stimulated about 9 ng/ml and 10 ng/ml 
TNF-a released from murine macrophages, respectively. 
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Figure 5.1. The standard curve of tumor necrosis factor-a (TNF-a) by TNF-a 
ELISA test kit “ 
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Figure 5.2a. The stimulatory effect of K1 CPS on the tumor necrosis factor-a 
(TNF-a) production of murine macrophage. BALB/c mice were injected i.p. with 
< 
3% thioglycollate. After 3 days, peritoneal macrophages were harvested and cultured 
with K1 CPS at different concentrations for 24 hours. The concentration ofTNF-a in 
50 i^l of culture supernatant were determined by TNF-a ELISA test kit. Tumor 
necrosis factor-a (TNF-a) concentration was found from tumor necrosis factor-a 
(TNF-a) standard curve. 
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Figure 5.2b. The stimulatory effect of K24 CPS on the tumor necrosis factor-a 
(TNF-a) production of murine macrophage. BALB/c mice were injected i.p. with 
< 
30/0 thioglycollate. After 3 days, peritoneal macrophages were harvested and cultured 
with K24 CPS at different concentrations for 24 hours. The concentration of TNF-
a in 50 ^ il of culture supematant were determined by TNF-a ELISA test kit. Tumor 
necrosis factor-a (TNF-a) concentration was found from tumor necrosis factor-a 
(TNF-a) standard curve. 
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5.2. Effect of Capsular Polysaccharides on the activities of MAPK family in 
murine macrophages 
It has previously been shown that all the three M A P K pathways, ERKs, JNK 
and p38, become activated in response to LPS (Han et al., 1994; Weinstein et al., 
1992; Dziarski et al.，1996). Also, it has been demonstrated that LPS-induced TNF-a 
production from macrophages is believed to be dependent on the activation o f M A P K 
pathways (Weinstein et al., 1991). W e suspected that CPS stimulated the TNF-a 
production by mimicking the effect of LPS on the M A P K pathways. Experiments 
were performed to confirm this point. 
r 
The effects of K1 and K24 capsular polysaccharides on the three M A P K 
pathways were examined. Macrophages were treated with K1 and K24 with different 
incubation time. It was found that Kl-induced expression ofactive ERK1 and active 
ERK2 peaked at 20 min and 10 min, respectively, and declined slightly by 60 min in 
two cases (Figure 5.3a & 5.3b). Also, it was found that K24-induced expression of 
active ERK1 and active ERK2 peaked at 10 min and 5 min, respectively, and 
declined slightly by 20 min in both cases (Figure 5.3a & 5.3b). ERK1 activation 
lasted longer for both K1 and K24 while ERK2 have a sharper peak. The expression 
of activated ERK1 is below resting level by 60 min upon K24 treatment. In the case 
ofJNK pathway, K1 induced the expression of active JNK1 with a peak at 30 min 
87 
and a decline to resting level by 60 min whereas K24 induced the expression of active 
JNK1 with a peak at 20 min and returned to resting level at 30 min (Figure 5.4). K1 
•^. 
induced the expression of active JNK2 with a peak at 20 min and a decline to resting 
level by 60 min whereas K24 induced the expression of active JNK2 with a peak at 
10 min and returned to resting level at 30 min (Figure 5.4). The time-course effects 
ofLPS on these two M A P K pathways were similar to those ofK24 (Figure 5.3a，5.3b 
& 5.4). K1 induced the expression of active p38 of the third M A P K pathway, p38 
pathway, with a peak at 20 min and returned to resting level at 30 min whereas K24 
induced the expression of active p38 with a peak at 10 min and a small decline at 30 
min (Figure 5.5a). The total amount of p38 increased upon K1, K24 and LPS 
treatment (Figure 5.5b). The time course of active p38 and total p38 expression is 
similar indicating that increased activation may be due to increase expression of total 
p38 alone or together with the activation of the kinase. The exact mechanism is not 
known 
The kinetics of activation of all M A P K family members by K1 were similar. 
In all cases, the peak activation of K24 on the expression of these proteins were 
reached in a shorter time when compared with K1. From the above findings, it could 
be concluded that K1 and K24 capsular polysaccharides could increase the expression 
of signaling proteins of the M A P K pathways. 
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Figure 5.3a. CPS-induced active ERK1 expression in murine macrophages. 
Murine macrophages were isolated from the peritoneal cavities of the thioglycollate-
r 
treated BALB/c mice. The macrophages were cultured with K1 (50^ ig/ml) / K24 
(50^g/ml) / LPS (l^ ig/ml) of different incubation times (0，5, 10，20，30，60). Triton-
X 100 soluble protein were prepared from the cells and were fractionated by 
SDS/PAGE, transferred to nitrocellulose and immunoblotted with active anti- active-
ERK1 antibodies. Antibody binding was visualized using an enhanced 
chemiluminescence detection system. 
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Figure 5.3b. CPS-induced active ERK2 expression in murine macrophages. 
Murine macrophages were isolated from the peritoneal cavities of the thioglycollate-
treated BALB/c mice. The macrophages were cultured with K1 (50^ igAnl) / K24 
(50^ ig/ml) / LPS (l^g/ml) ofdifferent incubation times (0, 5, 10，20, 30, 60). Triton-
X 100 soluble protein were prepared from the cells and were fractionated by 
SDS/PAGE, transferred to nitrocellulose and immunoblotted with anti- active-ERK2 
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Figure 5.4. CPS-induced active-JNKl/2 expression in murine macrophages. 
Murine macrophages were isolated from the peritoneal cavities of the thioglycollate-
treated BALB/c mice. The macrophages were cultured with K1 (50^ ig/ml) / K24 
(50^ ig/ml) / LPS (l^g/ml) of different incubation times (0, 5, 10, 20, 30, 60). Triton-
X 100 soluble protein were prepared from the cells and were fractionated by 
SDS/PAGE, transferred to nitrocellulose and immunoblotted with anti-active-JNKl/2 
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Figure 5.5a. CPS-induced active p38 expression in murine macrophages. 
Murine macrophages were isolated from the peritoneal cavities of the thioglycollate-
T 
treated BALB/c mice. The macrophages were cultured with K1 (50^ igAnl) / K24 
(50^ ig/ml) / LPS (l^ igAnl) of different incubation times (0, 5，10, 20，30，60). 
Cytoplasmic extracts were prepared from the cells. Triton-X 100 soluble protein were 
prepared from the cells and were fractionated by SDS/PAGE, transferred to 
nitrocellulose and immunoblotted with anti-active-p38 antibodies. Antibody binding 
was visualized using an enhanced chemiluminescence detection system. 
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Figure 5.5b. CPS-induced total-p38 expression in murine macrophages. Murine 
macrophages were isolated from the peritoneal cavities of the thioglycollate-treated 
BALB/c mice. The macrophages were cultured with K1 (50^ ig/ml) / K24 (50^ gy^ ml) / 
LPS (l^ ig/ml) of different incubation times (0, 5, 10, 20, 30, 60). Triton-X 100 
soluble protein were prepared from the cells and were fractionated by SDSy^AGE, 
transferred to nitrocellulose and immunoblotted with anti-total-p38 antibodies. 





ANTI-TUMOR ACTIVITIES ON MURINE TUMOR CELL LINES 
OF KLEBSIELLA K1 &K24 CAPSULAR POLYSACCHARIDES 
6.1. Effect of Kl and K24 Capsular Polysaccharides on the In vivo Anti-tumor 
Activities on EAT-bearing Mice 
BALB/c mice in group of five were injected intraperitoneally (i.p.). with 10^  
EAT cells on day 0. After five days, mice were treated with different concentrations 
(20 jag - 160 ^ ig/mduse/0.2 ml PBS/day) Kl or K24 antigens for four consecutive 
days. Figure 6.1a and 6.1b illustrate that both Kl and K24 could greatly suppress the 
growth of EAT cells in the peritoneal cavities of the mice. Both Kl and K24 
suppressed the growth of EAT cells in the peritoneal cavities of the mice in a dose-
dependent manner. Kl suppressed the EAT cell growth to about 50 % at the 
concentration of 20 ^ g/mouse, whereas K24 suppressed the EAT cell growth to about 
48 % at the concentration of 40 jug/mouse. 
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Figure 6.1a. Suppression of K1 CPS on EAT in different concentration 
in vivo. BALB/c mice in group of five were injected i.p. with 10^ EAT cells on day 0. 
K1 CPS antigen (20 - 160 ^ ig/mouse/day) was then injected i.p. for 4 consecutive 
< 
days (days 5 - 8) whereas control mice were injected with an equal volume of PBS. 
On day 9, EAT cells in the peritoneal cavity of each mouse were harvested by 
exhaustive drainage. Cells recovered were counted with a hemocytometer by the 
trypan blue exclusion method. Results were expressed as mean 土 S.D. 
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Figure 6.1b. Suppression of K24 CPS on EAT in different concentration in vivo. 
BALB/c mice in group of five were injected i.p. with 10^ EAT cells on day 0. K24 
CPS antigen (20 — 160 ^ ig/mouse/day) was then injected i.p. for 4 consecutive days 
(days 5 - 8) whereas tontrol mice were injected with an equal volume ofPBS. On day 
9, EAT cells in the peritoneal cavity of each mouse were harvested by exhaustive 
drainage. Cells recovered were counted with a hemocytometer by the trypan blue 
exclusion method. Results were expressed as mean 土 S.D. 
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6.2. In vivo Anti-tumor Effect on the Survival of EAT-Bearing Mice by 
Treatment o fKl and K24 CPS 
». 
BALB/c mice in group of ten were injected i.p. with 10^ E A T cells on day 0. 
CPS antigens were then injected i.p. into different group of mice. It was found that 
K1 CPS with the dose of 20^ig/mouse slightly prolonged the survival ofEAT-bearing 
mice in 4-day treatment group (Figure 6.2). Continuous treatment of K1 CPS was 
found to be more effective in prolonging the survival of EAT-bearing mice since it 
was shown that the survival of EAT-bearing mice in continuous treatment group was 
significantly prolonged by K1 CPS when compared to that of mice in control group 
(Figure 6.2). The result of the effect K24 CPS treatment was presented in Figure 6.3. 
< 
It was found that the effects ofK24 CPS on the survival ofEAT-bearing mice in both 
treatments were similar to those ofKl CPS. K24 CPS with the dose of 40^g/mouse 
slightly prolonged the survival of EAT-bearing mice in 4-day treatment group and 
significantly prolonged survival was found in continuous treatment. 
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Figure 6.2. Survival of EAT-Bearing Mice by Treatment of K1 CPS. BALB/c 
mice in group of ten were injected i.p. with 10^ EAT cells on day 0. K1 CPS antigen 
(20 ^ ig/mouse/day) was then injected i.p. for 4 consecutive days (days 5 - 8) in 4-day 
treatment and 26 consecutive days (days 5 - 30) in continuous treatment whereas 
control mice were injected with an equal volume of PBS. The mice in each group 
were observed daily for their survival. The mortality pattem of the EAT-bearing 
mice was determined and presented in term of survival rate (%). 
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Figure 6.3. Survival of EAT-Bearing Mice by Treatment of K24 CPS. BALB/c 
mice in group of ten were injected i.p. with 10^ EAT cells on day 0. K24 CPS antigen 
(40 |ig/mouse/day) was then injected i.p. for 4 consecutive days (days 5 - 8) in 4-day 
treatment and 26 consecutive days (days 5 - 30) in continuous treatment whereas 
control mice were injected with an equal volume of PBS. The mice in each group 
were observed daily for their survival The mortality pattem of the EAT-bearing 




ANTI-TUMOR ACTIVITIES OF COMBINED TREATMENT OF 
KLEBSIELLA K1 &K24 CAPSULAR POLYSACCHARIDES AND 
CHEMOTHERAPEUTIC DRUGS: ACTINOMYCIN D, 
CYCLOPHOSPHAMIDE AND DOXORUBICIN 
7.1. Cytotoxic Effect Chemotherapeutic Drugs: Actinomycin D (Act D), 
Cyclophosphamide (CY) and Doxorubicin (Dox), on WEHI-164 cell line 
Various concentrations of the chemotherapeutic drugs were co-
cultured with WEHI-164 cell line for studying the cytotoxicities of the drugs. 
It was found that the IC50 of actinomycin D on WEHI-164 cell was 0.2 juM 
(Fugure 7.1). The LC50 of cyclophosphamide and doxorubicin were 4 m M 
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Figure 7.1. Cytotoxic Effect of Actinomycin D on Wehi-164. WEHI-164 cells, 
with the cell concentration of 1 xlO^ cells/well, were seeded in 200 i^l RPMI 
complete medium in^6-well plate. After 24 hours, the original culture medium were 
removed and different concentrations of the Actinomycin D, which dissolved in 200 
^1 culture medium, were added to each well. The WEHI-164 cells were cultured with 
these drugs at 37。C for 24 hours. The cell viability was measured by neutral red 
assay. The % cytotoxicities of the drugs were calculated. Results were expressed as 
the arithmetic mean + S.D. of five samples. 
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Figure 7.2. Cytotoxic Effect of Cyclophosphamide on WEHI-164. WEHI-164 
cells, with the cell concentration of 1 xlO^ cells/well, were seeded in 200 ^ 1 RPMI 
complete medium in 96-well plate. After 24 hours, the original culture medium were 
< 
removed and different concentrations of the Cyclophosphamide, which dissolved in 
200 ^il culture medium, were added to each well. The WEHI-164 cells were cultured 
with these drugs at 37。C for 24 hours. The cell viability was measured by neutral red 
assay. The % cytotoxicities of the drugs were calculated. Results were expressed as 
the arithmetic mean + S.D. of flve samples. 
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Figure 7.3. Cytotoxic Effect ofDoxorubicin on WEHI -164. WEHI-164 cells, with 
the cell concentration of 1 xlO^ cells/well, were seeded in 200 jal RPMI complete 
medium in 96-well plate. After 24 hours, the original culture medium were removed 
and different concentrations of the Doxorubicin, which dissolved in 200 ^1 culture 
medium, were added to each well. The WEHI-164 cells were cultured with these 
drugs at 37°C for 24 hours. The cell viability was measured by neutral red assay. 
The % cytotoxicities of the drugs were calculated Results, were expressed as the 
arithmetic mean + S.D. of five samples. 
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7.2. Cytotoxic Effect of the Combined Treatment of the CPS and the 
. Chemotherapeutic Drugs (Act D, CY and Dox), on WEHI-164 cell line 
WEHI-164 cells were treated with different combinations of the drugs. K1 
capsular polysaccharide of 20 ^g/ml slightly suppressed the cell growth of 9 % 
(Figure 7.4). The % cytotoxicity of the combined treatment ofKl and actinomycin D 
(60.4 o/o) was similar to the sum of the % cytotoxicities of K1 and actinomycin D 
(52.4 %) (Figure 7.4). At the same time, the % cytotoxicity of the combined 
treatment with K1 and cyclophosphamide (57.2 %) is similar to the sum of the % 
cytotoxicities ofKl (11.1 %) and cyclophosphamide (48.3 %) (Figure 7.5). Similar 
result was found in the case of combined treatment with K1 and doxorubicin (Figure 
< 
7.6). The % cytotoxicity of the combined treatment with K1 and doxorubicin (57.6 
% ) is similar to the sum of the % cytotoxicities ofKl (9.0 %) and doxorubicin (51.0 
%). 
The in vitro cytotoxic effect of the combined treatment with K24 and the three 
drugs were presented in Figure 7.7 to Figure 7.9. The results illustrated that K24 had 
a similar effect to K1 in this part of experiment. 
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Figure 7.4. Cytotoxic Effect of the Combined Treatment of K1 and Actinomycin 
D on WEHI-164 cell line. WEHI-164 cells, with the cell concentration of 1 xlO^ 
cells/well, were seeded in 200 ^ il RPMI complete medium in 96-well plate. After 24 
hours, the original culture medium were removed and different combinations of drugs 
(Culture medium only, K1, Act D and K1 + Act D), which dissolved in 200 ^il culture 
medium, were added to each well. The WEHI-164 cells were cultured with these 
drugs at 37。C for 24 hours. The cell viability was measured by neutral red assay. 
The % cytotoxicities of the drugs were calculated. Results were expressed as % 
cytotoxicity 土 S.D. of five samples. 
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Figure 7.5. Cytotoxic Effect of the Combined Treatment of K1 and 
Cyclophosphamide on WEHI-164 cell line. WEHI-164 cells, with the 
cell concentration of 1 xlO^ cells/well, were seeded in 200 i^l RPMI 
complete medium in 96-well plate. After 24 hours, the original culture 
medium were removed and different combinations of drugs (Culture 
medium only, K l， C Y and K1 + CY), which dissolved in 200 ^ il culture 
medium, were added to each well. The WEHI-164 cells were cultured 
with these drugs at 37。C for 24 hours. The cell viability was measured by 
neutral red assay. The % cytotoxicities of the drugs were calculated. 
Results were expressed as % cytotoxicity 土 S.D. of five samples.‘ 
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Figure 7.6. Cytotoxic Effect of the Combined Treatment ofKl and Doxorubicin on 
WEHI-164 cell line. WEHI-164 cells, with the cell concentration of 1 xlO^ 
cells/well, were seeded in 200 ^ 1 RPMI complete medium in 96-well plate. After 24 
< 
hours, the original culture medium were removed and different combinations of drugs 
(Culture medium only, K1, Dox and K1 + Dox), which dissolved in 200 ^ 1 culture 
medium, were added to each well. The WEHI-164 cells were cultured with these 
drugs at 37。C for 24 hours. The cell viability was measured by neutral red assay. 
The % cytotoxicities of the drugs were calculated. Results were expressed as % 
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Figure 7.7. Cytotoxic Effect of the Combined Treatment of K24 and 
Actinomycin D on WEHI-164 cell line. WEHI-164 cells, with the cell 
concentration of 1 x>0^ cells/well, were seeded in 200 ^ il RPMI complete medium in 
96-well plate. After 24 hours, the original culture medium were removed and 
different combinations of drugs (Culture medium only, K24, Act D and K24 + Act 
D)，which dissolved in 200 ^il culture medium, were added to each well. The WEHI-
164 cells were cultured with these drugs at 37°C for 24 hours. The cell viability was 
measured by neutral red assay. The % cytotoxicities of the drugs were calculated. 
Results were expressed as % cytotoxicity 土 S.D. of five samples. 
108 
100 n . 
- 乏 80  
Nwi^ 
0 60 ^ | ^ ^ ^ ^ 
1 ：' ^ m — ^ 
p ^ _ • — 
U H i______i 1 1 1 
K24 CY 4mM K24 + CY 4mM 
Figure 7.8. Cytotoxic Effect of the Combined Treatment of K24 and 
Cyclophosphamide on WEHI-164 cell line. WEHI-164 cells, with the cell 
concentration of 1 xlO^ cells/well, were seeded in 200 ^ il RPMI complete medium in 
96-well plate. After 24 hours, the original culture medium were removed and 
different combinations of drugs (Culture medium only, K24, C Y and K24 + CY), 
which dissolved in 200 ^ il culture medium, were added to each well. The WEHI-164 
cells were cultured with these drugs at 37。C for 24 hours. The cell viability was 
measured by neutral red assay. The % cytotoxicities of the drugs were calculated. 
Results were expressed as % cytotoxicity 土 S.D. of five samples. 
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Figure 7.9. Cytotoxic Effect of the Combined Treatment of K24 and 
Doxorubicin on WEHI-164 cell line. WEHI-164 cells, with the cell concentration 
of 1 xlC)4 cells/well, were seeded in 200 ^ 1 RPMI complete medium in 96-well plate. 
After 24 hours, the original culture medium were removed and different combinations 
f 
of drugs (Culture medium only, K24, Dox and K24 + Dox), which dissolved in 200 
[il culture medium, were added to each well. The WEHI-164 cells were cultured with 
these drugs at 37。C for 24 hours. The cell viability was measured by neutral red 
assay. The % cytotoxicities of the drugs were calculated. Results were expressed as 
% cytotoxicity 土 S.D. of fIve samples. 
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7.3. Anti-Tumor Effect of Chemotherapeutic Drugs (Act D, CY and Dox) on 
！ EAT-bearing Mice in vivo 
To study the in vivo anti-tumor effect of the chemotherapeutic drugs, EAT-
bearing mice were treated with different concentrations of the drugs. It was found 
that the % suppression ofEAT growth increase with the dose of all three drugs. The 
LC50 of actinomycin D, cyclophosphamide and doxorubicin were 2 ^ig/mouse, 2 
mg/mouse and 2 |ig/mouse, respectively (Figure 7.10 to Figure 7.12). 
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Figure 7.10. Anti-Tumor Effect of Actinomycin D on EAT-bearing Mice 
in vivo. BALB/c mice in group of five were injected i.p. with 10^ EAT cells 
r 
on day 0. Actinomycin with various concentrations was then injected i.p. at 
day 5 whereas control mice were injected with an equal volume of PBS. On 
day 9, EAT cells in the peritoneal cavity of each mouse were harvested by 
exhaustive drainage. Cells recovered were counted with a hemocytometer by 
the trypan blue exclusion method. Results were expressed as mean 土 S.D. 
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Figure 7.11. Anti-Tumor Effect of Cyclophosphamide on EAT-bearing 
Mice in vivo. BALB/c mice in group of five were injected i.p. with 10^ EAT 
cells on day 0. Cyclophosphamide, with various concentrations, was then 
injected i.p. a$ day 5 whereas control mice were injected with an equal volume 
of PBS. On day 9, EAT cells in the peritoneal cavity of each mouse were 
harvested by exhaustive drainage. Cells recovered were counted with a 
hemocytometer by the trypan blue exclusion method. Results were expressed 
as mean 土 S.D. 
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Figure 7.12. Anti-Tumor Effect of Doxorubicin on EAT-bearing Mice in 
v / v a BALB/c mice in group of five were injected i.p. with 10^ EAT cells on 
day 0. Doxorubicin with various concentrations was then injected i.p. at day 5 
< 
whereas control mice were injected with an equal volume of PBS. On day 9, 
EAT cells in the peritoneal cavity of each mouse were harvested by 
exhaustive drainage. Cells recovered were counted with a hemocytometer by 
the trypan blue exclusion method. Results were expressed as mean 土 S.D. 
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7.4. Combined Treatment of the CPS and Chemotherapeutic Drugs (Act D, CY 
- and Dox) on the EAT Growth in vivo 
In this experiment, EAT-bearing mice were used as model to study the in vivo 
anti-tumor effect of combined treatment of capsular polysaccharides and the 
chemotherapeutic drugs. Response of BALB/c mice being E A T carcinoma to 
immunotherapy with K1 or K24, to chemotherapy with Act D, C Y or Dox, or both 
forms of therapy used in conjunction was presented in Figure 7.13 to Figure 7.18. 
IC50 of each drug was chosen as the concentration used for the treatment. It was 
found that the combined treatment of immunotherapy (K1) and chemotherapy (Act D, 
C Y or Dox) greatly suppressed the EAT growth up to 85.9 % (Figure 7.13)，79.1 % 
< 
(Figure 7.14) and 77.9 % (Figure 7.15), respectively. 
The combination of immunostimulatory drug, K24, together with 
chemotherapy with Act D， C Y or Dox, also suppressed the EAT growth greatly up to 
70.3 % (Figure 7.16), 85.6 % (Figure 7.17) and 82.4 % (Figure 7.18), respectively. 
Whatever using K1 or K24 for immunotherapy and Act D, C Y or Dox for 
chemotherapy, the combined treatment resulted in additive effect on the in vivo anti-
tumor activity on EAT growth. 
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Figure 7.13. Combined Treatment of Kl and Actinomycin D on EAT 
Growth in vivo. BALB/c mice in group of five were injected i.p. with 10^  
EAT cells orfday 0. Kl was then injected i.p. for 4 consecutive days (days 5 -
8) whereas control mice were injected with an equal volume of PBS. 
However, Actinomycin D was injected i.p. into mice only on day 5 (one 
dose). On day 9, EAT cells in the peritoneal cavity of each mouse were 
harvested by exhaustive drainage. Cells recovered were counted with a 
hemocytometer by the trypan blue exclusion method. Results were expressed 
as mean± S.D. 
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Figure 7.14. Combined Treatment o f K l and Cyclophosphamide on EAT 
Growth in vivo. BALB/c mice in group of five were injected i.p. with 10^  
EAT cells on day 0. K1 was then injected i.p. for 4 consecutive days (days 5 -
< 
8) whereas control mice were injected with an equal volume of PBS. 
However, Cyclophosphamide was injected i.p. into mice only on day 5 (one 
dose). On day 9, EAT cells in the peritoneal cavity of each mouse were 
harvested by exhaustive drainage. Cells recovered were counted with a 
hemocytometer by the trypan blue exclusion method. Results were expressed 
asmean±S.D. 
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Figure 7.15. Combined Treatment of K1 and Doxorubicin on EAT-
Growth in vivo. BALB/c mice in group of five were injected i.p. with 10^  
EAT cells on day 0. K1 was then injected i.p. for 4 consecutive days (days 5 -"t 
8) whereas control mice were injected with an equal volume of PBS. 
However, Doxorubicin was injected i.p. into mice only on day 5 (one dose). 
On day 9, EAT cells in the peritoneal cavity of each mouse were harvested by 
exhaustive drainage. Cells recovered were counted with a hemocytometer by 
the trypan blue exclusion method. Results were expressed as mean 土 S.D. 
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Figure 7.16. Combined Treatment of K24 and Actinomycin D on EAT 
Growth in vivo. BALB/c mice in group of five were injected i.p. with 10^ 
EAT cells on day 0. K24 was then injected i.p. for 4 consecutive days (days 5 
-8) whereas control mice were injected with an equal volume of PBS. 
However, Actinomycin D was injected i.p. into mice only on day 5 (one 
dose). On day 9, EAT cells in the peritoneal cavity of each mouse were 
harvested by exhaustive drainage. Cells recovered were counted with a 
hemocytometer by the trypan blue exclusion method. Results were expressed 
as mean 土 S.D. 
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Figure 7.17. Combined Treatment of K24 and Cyclophosphamide on 
EAT Growth in vivo. BALB/c mice in group of five were injected i.p. with 
10^ EAT cells on day 0. K24 was then injected i.p. for 4 consecutive days 
(days 5 - 8) whereas control mice were injected with an equal volume ofPBS. 
However, Cyclophosphamide was injected i.p. into mice only on day 5 (one 
dose). On day 9, EAT cells in the peritoneal cavity of each mouse were 
harvested by exhaustive drainage. Cells recovered were counted with a 
hemocytometer by the trypan blue exclusion method. Results were expressed 
asmean±S.D. 
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Figure 7.18. Combined Treatment of K24 and Doxorubicin on EAT 
Growth in vivo. BALB/c mice in group of five were injected i.p. with 10^  
EAT cells on day 0. K24 was then injected i.p. for 4 consecutive days (days 5 
< 
-8) whereas control mice were injected with an equal volume of PBS. 
However, Doxorubicin was injected i.p. into mice only on day 5 (one dose). 
On day 9, EAT cells in the peritoneal cavity of each mouse were harvested by 
exhaustive drainage. Cells recovered were counted with a hemocytometer by 
the trypan blue exclusion method. Results were expressed as mean 土 S.D. 
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7.5. Combined Treatment of the CPS and Chemotherapeutic Drugs (Act D, CY 
and Dox) on the Survival of EAT-bearing Mice in vivo 
In the previous part, it has been shown that the combined treatment of CPS 
and chemotherapeutic drugs could augment the anti-tumor effect on the EAT growth 
in vivo. Experiments were performed to investigate the effect of combined treatment 
on the survival of tumor bearing mice. Response of EAT-bearing mice to 
immunotherapy with Kl or K24, to chemotherapy with Act D, C Y or Dox, or both 
forms of therapy used in conjunction was presented in Figure 7.19a to Figure 7.24b. 
All mice in the control groups of different sets of experiments died within 17 to 18 
days. In general, the survival rate started to decline greatly from day 12 and all the 
< 
mice in control group died within dayl7 to 18. When the mice were treatment with 
chemotherapeutic drug (Act D, C Y or Dox) alone, the survival was prolonged by 3 to 
5 days. The survival of Kl and K24 treated mice were prolonged by 5 days. On the 
other hand, the complete course of chemotherapy (Act D, C Y or Dox) and 
immunotherapy (Kl or K24) produced remarkably beneficial effects resulting in 
prolonged survival of EAT-bearing mice up to 10 days. Moreover, in the combined 
treatments of Kl and Act D, and Kl and Dox (continous treatment), one out of ten 
mice remained survive even after 30 days. Finally, it was found that continuous 
treatment was found to be more effective than 4-day treatment in prolonging the 
survival of EAT-bearing mice. 
122 
120"p  
, 1 0 0 m W i m -4-Control 
I 80j ^ + K i 
> 6 0 ^  
I 4 0 % ^ ActD 
的 2 0 V V ^ f  
1 \ \ -)(-Kl+ActD 
0 H~~^——I 1 1~~k^vHjjjy^mm  
0 5 10 15 20 25 30 35 
Time (days) 
Figure 7.19a. Combined Treatment o f K l and Actinomycin D on the Survival of 
EAT-bearing Mice in vivo (4-day treatment). BALB/c mice in group of ten were 
injected i.p. with 10^  E A T cells on day 0. K1 was then injected i.p. for 4 consecutive 
days (days 5 - 8) whereas control mice were injected with an equal volume of PBS. 
However, actinomycin D was injected i.p. into mice only on day 5 (one dose). The 
mice in each group were observed daily for their survival. The mortality pattem of 
the EAT-bearing mice was determined and presented in term of survival rate (%). 
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Figure 7.19b. Combined Treatment o f K l and Actinomycin D on the Survival of 
EAT-bearing Mice in vivo (continuous treatment). BALB/c mice in group of ten 
were injected i.p. with 10^ E A T cells on day 0. Kl was then injected i.p. for 26 
consecutive days (days 5 - 30) whereas control mice were injected with an equal 
volume ofPBS. However, actinomycin D was injected i.p. into mice only on day 5 
(one dose). The mice in each group were observed daily for their survival. The 
mortality pattem of the EAT-bearing mice was determined and presented in term of 
survival rate (%). 
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Figure7.20a. Combined Treatment of K1 and Cyclophosphamide on the 
Survival of EAT-bearing Mice in vivo (4-day treatment). BALB/c mice in group 
of ten were injected i.p. with 10^ E A T cells on day 0. K1 was then injected i.p. for 4 
consecutive days (days 5 - 8) whereas control mice were injected with an equal 
volume ofPBS. However, cyclophosphamide was injected i.p. into mice only on day 
5 (one dose). The mice in each group were observed daily for their survival. The 
mortality pattem of the EAT-bearing mice was determined and presented in term of 
survival rate (%). 
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Figure 7.20b. Combined Treatment of K1 and Cyclophosphamide on the 
Survival of EAT-bearing Mice in vivo (continuous treatment). BALB/c mice in 
group of ten were injected i.p. with 10^ EAT cells on day 0. K1 was then injected i.p. 
for 26 consecutive days (days 5 - 30) whereas control mice were injected with an 
equal volume ofPBS. However, cyclophosphamide was injected i.p. into mice only 
on day 5 (one dose). The mice in each group were observed daily for their survival. 
The mortality pattem of the EAT-bearing mice was determined and presented in term 
of survival rate (%)• 
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Figure 7.21a. Combined Treatment of K1 and Doxorubicin on the Survival of 
EAT-bearing Mice in vivo (4-day treatment). BALB/c mice in group of ten were 
injected i.p. with 10^  E A T cells on day 0. K1 was then injected i.p. for 4 consecutive 
days (days 5 - 8) whereas control mice were injected with an equal volume of PBS. 
However, doxorubicin was injected i.p. into mice only on day 5 (one dose). The mice 
in each group were observed daily for their survival. The mortality pattem of the 
EAT-bearing mice was determined and presented in term of survival rate (%). 
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Figure 7.21b. Combined Treatment of K1 and Doxorubicin on the Survival of 
EAT-bearing Mice in vivo (continuous treatment). BALB/c mice in group of ten 
were injected i.p. with 10^ E A T cells on day 0. K1 was then injected i.p. for 26 
consecutive days (days 5 - 30) whereas control mice were injected with an equal 
volume ofPBS. However, doxorubicin was injected i.p. into mice only on day 5 (one 
dose). The mice in each group were observed daily for their survival. The mortality 
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Figure 7.22a. Combined Treatment of K24 and Actinomycin D on the Survival 
of EAT-bearing Mice in vivo (4-day treatment). BALB/c mice in group of ten 
were injected i.p. with 10^ E A T cells on day 0. K24 was then injected i.p. for 4 
consecutive days (days 5 - 8) whereas control mice were injected with an equal 
volume of PBS. However, actinomycin D was injected i.p. into mice only on day 5 
(one dose). The mice in each group were observed daily for their survival. The 
mortality pattem of the EAT-bearing mice was determined and presented in term of 
survival rate (%). 
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Figure 7.22b. Combined Treatment ofK24 and Actinomycin D on the Survival 
of EAT-bearing Mice in vivo (continuous treatment). BALB/c mice in group of 
ten were injected i.p. with 10^ EAT cells on day 0. K24 was then injected i.p. for 26 
consecutive days (days 5 - 30) whereas control mice were injected with an equal 
volume ofPBS. However, actinomycin D was injected i.p. into mice only on day 5 
(one dose). The mice in each group were observed daily for their survival. The 
mortality pattem of the EAT-bearing mice was determined and presented in term of 
survival rate (%)• 
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Figure 7.23a. Combined Treatment of K24 and Cyclophosphamide on the 
Survival of EAT-bearing Mice in vivo (4-day treatment). BALB/c mice in group 
of ten were injected i.p. with 10^ EAT cells on day 0. K24 was then injected i.p, for 4 
consecutive days (days 5 - 8) whereas control mice were injected with an equal 
volume ofPBS. However, cyclophosphamide was injected i.p. into mice only on day 
5 (one dose). The mice in each group were observed daily for their survival. The 
mortality pattern of the EAT-bearing mice was determined and presented in term of 
survival rate (%). 
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Figure 7.23b. Combined Treatment of K24 and Cyclophosphamide on the 
Survival of EAT-bearing Mice in vivo (continuous treatment). BALB/c mice in 
group often were injected i.p. with 10^ EAT cells on day 0. K24 was then injected i.p. 
for 26 consecutive days (days 5 - 30) whereas control mice were injected with an 
equal volume ofPBS. However, cyclophosphamide was injected i.p. into mice only 
on day 5 (one dose). The mice in each group were observed daily for their survival. 
The mortality pattem of the EAT-bearing mice was determined and presented in term 
of survival rate (%). 
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Figure 7.24a. Combined Treatment of K24 and Doxorubicin on the Survival of 
EAT-bearing Mice in vivo (4-day treatment). BALB/c mice in group often were 
injected i.p. with 10^ EAT cells on day 0. K24 was then injected i.p. for 4 consecutive 
days (days 5 - 8) whereas control mice were injected with an equal volume ofPBS. 
However, Doxorubicin was injected i.p. into mice only on day 5 (one dose). The mice 
in each group were observed daily for their survival. The mortality pattem of the 
EAT-bearing mice was determined and presented in term of survival rate (%). 
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Figure 7.24b. Combined Treatment of K24 and Doxorubicin on the Survival of 
EAT-bearing Mice in vivo (continuous treatment). BALB/c mice in group often 
were injected i.p. with 10' EAT cells on day 0. K24 was then injected i.p. for 26 
consecutive days (days 5 - 30) whereas control mice were injected with an equal 
volume ofPBS. However, doxorubicin was injected i.p. into mice only on day 5 (one 
dose). The mice in each group were observed daily for their survival. The mortality 






8.1. Extraction, Purification and Characterization of K1 and K24 Capsular 
Polysaccharides from Klebsiella pneumoniae Serotype 1 and Serotype 24 
Previous studies showed that many polysaccharide fractions from various 
natural plants were found to have immunostimulatory (Kok et al., 1995; Wong et al., 
1994a; Buzzi et al., 1992) or even anti-tumor effects (Wong et al., 1994c; Leung et 
< 
al., 1997; Takahashi et al., 1988). Hot-water extraction followed by various 
chromatographic methods are usually used to purify these bioactive polysaccharides 
(Wong et aL, 1994a). However, these methods are very tedious and the fractions are 
heterogeneous. 
In our study, Cetavlon and alcohol precipitation followed by gel filtration are 
employed to purify the K1 and K24 capsular polysaccharides (CPS). Cetavlon, a 
cationic detergent, precipitates the acidic macromolecules from the crude 
polysaccharide fractions. Thus, the impurities, which cannot bind to Cetavlon, can be 
removed. The precipitate was then redissolved in 4 M NaCl. After alcohol 
precipitation, Cetavlon and NaCl can be removed and purified CPS are resulted. The 
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purified CPS were dried by lyophilization. It was found that the purification method 
、. used gives good yields of purified K1 and K24 CPS from the crude polysaccharide 
fractions up to 50.21 % and 62.10 % respectively. Thus, Cetavlon and alcohol 
precipitation is a relatively simple and efficient method to purify acidic capsular 
polysaccharides from crude polysaccharide fractions. 
The homogenicities and molecular weights were estimated by gel filtration. 
By gel chromatography using Sepharose CL-2B column, a single peak was observed 
in the elution profile ofKl (Figure 4.1b), indicating that K1 capsular polysaccharide 
might be a homogeneous compound. In the elution profile ofK24 (Figure 4.1c), only 
a single peak was found, implying that K24 capsular polysaccharide might be 
< 
homogenous. The estimated molecular weight of K1 capsular polysaccharide was 
found to be between 2 x 10^ and 5 x 10^. On the other hand, K24 capsular 
polysaccharide was eluted near the void volume, indicating that the estimated 
molecular weight was slightly less than 5 x 10^. Actually, K1 and K24 capsular 
polysaccharides were found to consist of thousands of oligosaccharide repeating 
units, and the number of units might vary and hence the polysaccharide fragments 
with different length and molecular weights (Choy et al., 1973; Erbing et al., 1976). 
It is difficult to determine the exact molecular weights ofboth K1 and K24 CPS. 
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K1 and K24 capsular antigens were found to consist of mainly carbohydrate 
、 (determined by both sulfuric acid method and carbozole reaction) and trace amounts 
of protein (Table 4.1). Similar finding was reported in the study of Klebsiella K7 
capsular antigen (Cryz et al., 1985). Both K1 and K24 capsular antigens contain 
significant amount of uronic acid up to 30.2 % and 20.2 % respectively. The uronic 
acid content may contribute to the acidities of the CPS. More important, the high 
uronic acid content of capsular polysaccharides may contribute to their 
immunostimulatory and anti-tumor effects. This is consistent with the previous study 
on the crude polysaccharide fractions from the Chinese medicine Pseudostellaria 
heterophylla. These findings showed that the polysaccharide fractions from 
Pseudostellaria heterophylla contain high level of uronic acid and processes various 
< 
immunostimulatory and anti-tumor effects (Wong et aL, 1994a; Wong et al., 1994b; 
Wong et al., 1994c). Since K1 and K24 capsular polysaccharides have well-defined 
repeating units (Figure 8.1 & 8.2) can be prepared in large quantities by relative 
simple procedures and have potent immunostimulatory and anti-tumor activities 
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8.2. Effect of Kl and K24 Capsular Polysaccharides on the Macrophage 
, Activation 
Macrophage is one of the effector cells mediating anti-tumor immunity. 
Macrophages can selectively kill the malignant (transformed) cells while leaving the 
non-malignant (normal) cells unharmed (Fidler and Schroit, 1988). When 
macrophages contact with tumor target cells, macrophages recognize and bind to the 
tumor target cells. Macrophages kill the tumor target cells by secretion of cytokines 
such as TNF-a (Frei and Spriggs, 1989). 
In this study, we found that both Kl and K24 capsular polysaccharides < 
exerted strong effects on TNF-a production from murine peritoneal macrophages in 
vitro (Figure 5.2a &5.2b). LPS was found to induce TNF-a production from murine 
macrophages (Beutler et al., 1985). However, LPS cause adverse effects, such as 
tissue injury and shock, to the hosts (Morrison and Tyan, 1979). Kl and K24 may be 
a better immunostimulating agent than LPS since the Kl and K24 treatment were not 
harmful to the hosts (mice). 
Although many bacterial polysaccharides, including Kl and K24 CPS, were 
found to have immunostimulatory activities on anti-tumor effector cells, such as 
macrophage (Choy et al., 1996; Cavaillon et aL, 1990)，the mechanism of the effect 
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of CPS on the signal transduction pathways was unknown. LPS is one of the 
, bacterial polysaccharides that were comparatively well studied on the effect on the 
signal transduction pathways ofTNF-a biosynthesis (Geppert et aL, 1994; Swantek et 
al.，1997; Schafer et aL, 1999) It is believed that LPS induced the TNF-a production 
from macrophages through activation of mitogen-activated protein kinase (MAPK) 
signaling pathways (Geppert et aL, 1994; Swantek et al., 1997). Therefore, to study 
the effect of CPS on the signal transduction pathway, the effect of CPS on the M A P K 
signaling pathways were investigated. 
It has been shown that K1 and K24 CPS activated ERK1 and ERK2, p38 and 
JNK expressions in murine macrophages. LPS has the same effect on expression of 
< 
these proteins in macrophages (Swantek et aL, 1997; Geppert et al., 1994). 
Moreover, LPS was found to activate M E K 1 and M E K 4 (upstream regulators of 
ERK1 and ERK2 and ofJNK respectively) (Swantek et aL, 1997). LPS also activates 
MEK2, -3, and —6 (upstream regulators of ERK1 and ERK2), and of p38, 
respectively (Swantek et aL, 1997). K1 and K24 CPS might also upregulate the 
activities of these upstream regulators o f M A P K pathways. In order to show a clearer 
picture ofhow K1 and K24 CPS activate the M A P K signaling pathways, it is worthy 
to study the effect ofKl and K24 CPS on these upstream regulators. 
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The LPS signaling cascade leading to TNF-a production by controlling both 
、 transcription of the TNF-a gene and translation of TNF-a (Beutler et al., 1985). JNK 
was shown to involve in the regulation of TNF-a biosynthesis at the level of 
translation (Swantek et al., 1997). p38 are also required for translational regulation of 
TNF-a. Furthermore, upstream components in the E R K pathway, Ras and Raf, are 
required for TNF-a production at the level of both transcription and translation 
(Geppert et al., 1994). Based on the above findings, The signaling mechanisms of 
LPS-induced TNF-a biosynthesis is proposed in Figure 8.3 (Swantek et al., 1997). It 
is believed that CPS activate the TNF-a production by mimicking the signaling 
mechanism of LPS leading to TNF-a biosynthesis. The signaling mechanisms of 
CPS-induced TNF-al3iosynthesis is proposed in Figure 8.4. 
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Figure 8.3. The signaling mechanisms of LPS-induced TNF-a biosynthesis. 
Relationships supported by data in the literature (solid arrows) and unknown 
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Figure 8.1. Proposed signaling mechanisms of CPS-induced TNF-a biosynthesis. 
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8.3. Anti-tumor Activities on Murine Tumor Cell Lines of Klebsiella K1 and 
� K24 Capsular Polysaccharides 
Previous studies showed that K1 and K24 capsular polysaccharides exerted 
only little cytostatic effects on the murine cell lines such as EAT carcinoma, L929 
fibrosarcoma and WEHI-164 fibrosarcoma, in vitro. However, in my study, it was 
found that K1 and K24 can suppress the EAT cell growth in vivo. Both K1 and K24 
suppressed the growth of EAT cells in the peritoneal cavities of the mice in a dose-
dependent manner. K1 suppressed the EAT cell growth to about 50 % at the 
concentration of 20 ^ g/mouse, whereas K24 suppressed the EAT growth to about 40 
% at the concentration of 40 ^ ig/mouse. It was reported that K1 and K24 CPS could 
< 
induce TNF-a secretion in mice (Choy et al., 1996). The reason for the suppression 
of EAT growth in vivo is probably mediated through the activation of the host 
immune system rather than resulting from the direct cytotoxicity on tumor cells. K1 
and K24 CPS are well known to contain abundant amount of glucuronic acid, similar 
to Pseudostellaria heterophylla fractions (Wong et al., 1992) in which the high uronic 
acid content may be essential for its potent anti-tumor activity. The glucuronic acid in 
K1 and K24 CPS may play an important role in mediating the suppression of EAT 
cell growth in vivo. 
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The clinical trials of direct injection of human recombinant TNF had been 
、 carried out in cancer treatment, but resulting in many toxic side effects including 
cachexia and fever (Frei, III and Spriggs, 1989; Taguchi et al.，1992). Therefore, a 
safer and more effective alternative for cancer treatment is to activate the immune 
system to induce endogenous TNF production so as to suppress tumor growth. LPS 
was found to be a potent TNF eliciting agent but LPS can cause many toxic side 
effects including marked hypotension, fever and endotoxin shock (Ha et al., 1985; 
Morrison and Raziuddin, 1982), which are caused by the toxic component lipid A 
(Old, 1988). K1 and K24 CPS may be good candidates as TNF eliciting agents. In 
the previous part, it was found that K1 and K24 CPS exerted potent effects on TNF-a 
production from murine peritoneal macrophages. The anti-tumor effects of K1 and 
r 
K24 CPS may be contributed by the K1 and K24 CPS-induced endogenous TNF-
a production in mice. K1 and K24 may be a good agent for eliciting endogenous 
TNF-a production, thus exert anti-tumor activities. 
In the survival experiment, both K1 and K24 prolonged the survival of EAT-
bearing mice (Figure 6.2 & 6.3). This can be explained by the anti-tumor effects of 
K1 and K24 CPS. In the previous part, K1 and K24 were found to have great 
suppression on the EAT growth in the peritoneal cavities of mice. Therefore, K1 and 
K24 could prolong the survival of the experimental animals to a certain extent. It was 
found that the effect of continuous CPS treatment was better than that of 4-day CPS 
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treatment. Since K1 and K24 CPS exert their anti-tumor activities by activating the 
immune system of the host to fight against the tumor cells, continuous treatment of ,. 
CPS may keep the host's immune system active and defend the tumor cells. Thus, 
this can be more effective in prolonging the survival of the mice. 
< 
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8.4. Anti-tumor Activities of Combined Treatment of K1 and K24 Capsular 
� Polysaccharides and Chemotherapeutic Drugs: Actinomycin D, 
Cyclophosphamide and Doxorubicin 
Chemotherapy is one of the most widely used treatments for cancer patients. 
The classic treatment of cancer by chemotherapy can result in improvement or even 
the cure of some types of cancer but toxic-side effects often impair the final result of 
therapy. It is because chemotherapeutic drugs kill the tumor cells, and at the same 
time, they are toxic to normal tissues. Therefore, many researchers are trying to find 
out the ways of how to target the chemotherapeutic drugs only to the tumor site or 
reduce the toxic-side effects by combination of chemotherapy with other treatment, 
< 
such as immunotherapy. Since many chemotherapeutic drugs induce depression in 
the function of the immune system (Eremin, 1992), the combined treatment of 
chemotherapy and immunotherapy is deserved for study. It has been reported that 
combination of immunotherapy with chemotherapy could augment the anti-tumor 
effect in experiment animals (Lasek et aL, 1995; Das et al., 1989) and even in patients 
(Shiu et al., 1993). Therefore, the anti-tumor effect of the administration of 
immunomodulatory CPS with thechemotherapeutic drugs, actinomycin D (Act D)， 
cyclophosphamide (CY) and doxorubicin (Dox), was studied. 
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First, the cytotoxic effects of the three drugs on tumor cells in vitro were 
, examined for determining the LC50 of each drug (Figure 7.1 to 7.3). The LC50 of 
each drug is used for the concentration of the drug in the experiment of combined 
treatment. It seemed that there are additive effects on the combined treatments 
(Figure 7.4 to 7.9). However, K1 and K24 CPS only slightly suppressed the WEHI-
164 cell growth and the chemotherapeutic drugs contributed most of the cytotoxicity. 
Therefore, it could be possible that K1 and K24 CPS could not augment the anti-
tumor activities of the chemotherapeutic drugs on the WEHI-164 cells in vitro. 
Again, the in vivo anti-tumor effects of the three drugs were studied for 
determining the LD50 of each drug (Figure 7.10 to7.12). The LD50 of each drug is 
< 
used for the concentration of the drug in the experiment of combined treatment. It 
was found the combined treatment of immunotherapy (K1 and K24) and 
chemotherapy (Act D, C Y and Dox) resulted in additive effect on the in vivo anti-
tumor activity on E A T growth (Figure 7.13 to 7.18). Also, the combined treatment 
resulted in significant prolongation of survival of the EAT-bearing mice (Figure 
7.19a to 7.24b) 
C Y was found to be cytotoxic, kill rapidly dividing neoplastic and normal 
cells and has drastic effects on cells of the immune system. It is a 
immunosuppressive drug that both humoral and cellular immune function may be 
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inhibited to a varying degree by C Y (Eremin, 1992). It has been reported that 
^ Polysaccharide Peptide (PSP) isolated from Coriolus versicolor could restores 
immunosuppression induced by cyclophosphamide in rats (Qian et al., 1997). 
Therefore, the beneficial effect of combined treatment of K1 or K24 CPS, and C Y 
may be due to the reason that immunostimulatory CPS restores immunosuppression 
in the body of host, resulting a addictive effect on the suppression of EAT growth in 
vivo and significant prolongation of survival of the EAT-bearing mice. C Y can result 
in not only immunosuppression but also immunopotentiation (Mastrangelo et al., 
1986; Eremin, 1992) depending on the regimen employed, type of antigen and its 
timing and route of administration, and the immuno-parameters studied. C Y could 
enhance of Delay Type Hypersensitivity (DTH) responsiveness when it was used 1 — 
< 
2 days before sensitization (Turk and Parker, 1982). This immunopotentiating effect 
resulted probably from impairment of T-suppressor cell function (Brooks-Kaiser et 
al., 1993). This immunopotentiating effect of C Y may also contributed to the 
beneficial effect on combined treatment. 
Phase I clinical trial have been carried out on colorectal carcinomas and soft 
tissue sarcomas using recombinant human TNF as immunotherapeutic agents and the 
tumor regressions were resulted (Borden and Sondel, 1990). Also, the cytotoxicity of 
TNF was potentiated by chemotherapeutic drugs including actinomycin D and 
doxorubicin (Spriggs, 1991). It was found that TNF-a could exert potent cytotoxic 
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effect in vitro when combined with some chemotherapeutic drugs such as 
、 actinomycin D and doxorubicin. The mechanism of this synergistic effect is not 
known. On the other hand, CPS could stimulate the host's immune system to 
produce cytokines, including TNF-a, and activate anti-tumor effector cells such as 
macrophages, CTL and N K cells. Therefore, Kl and K24 CPS may augment the 
anti-tumor effect of actinomycin D and doxorubicin and thus prolong the survival of 
EAT-bearing mice. Furthermore, treatment of tumor cells with actinomycin D 
enhances considerably their susceptibility to killing by monocytes (Colotta et al., 
1985). This may also contribute to the additive effect of CPS and actinomycin D on 
the suppression on EAT growth and prolonging the survival. 
T 
In summary, these results demonstrate that Kl and K24 CPS possess 
immunostimulatory effects and anti-tumor effects. CPS may potentiate the cytotoxic 
effect of chemotherapeutic agents, including actinomycin D, cyclophosphamide and 
doxorubicin, by their immunopotentiative activity. CPS may be use as a useful 
adjuvant in clinical treatment of cancer patients. The studies of CPS offer a new 
approach increasing not only the therapeutic index but also reducing side effects 




CONCLUSIONS AND FUTURE PERSPECTIVES 
Capsular polysaccharides (CPS) are isolated from the capsule of the bacteria 
Klebsiella pneumoniae and purified by Cetavlon and alcohol precipitation. Previous 
studies on Klebsiella capsular polysaccharides were concentrated on their vaccine 
potential (Cryz, Jr. et al., 1985a; Cryz, Jr. et al., 1985b). Kl and K24 CPS were 
found to process a wide variety of immunomodulatory and anti-tumor activities. 
< 
It has been shown that Kl and K24 CPS could stimulate the tumor necrosis 
factor-alpha (TNF-a) production from murine peritoneal macrophages (Chapter 5). 
The underlying mechanism of the CPS-induced TNF-a production from macrophages 
was studied. It was found that Kl and K24 CPS activated the expressions of mitogen-
activated protein kinase (MAPK) signaling proteins, including ERK1 and ERK2, p38 
and JNK, in murine macrophages. Therefore, one possible mechanism is that CPS 
induced TNF-a production from macrophages through M A P K signaling pathway. 
However, many further investigations are required to confirm this point. It is believed 
that CPS activate the TNF-a production by mimicking the effect of LPS on the 
signaling pathways leading to TNF-a biosynthesis. 
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The glycosylphosphatidyl-inositol-anchored monocytic differentiation antigen, 
, CD14, has been identified as a cell-surface receptor for LPS in monocytes (Wright et 
al., 1990). Also, it was shown that CD14 involved in stimulation of cytokine 
production by uronic acid polymers (Espevik et aL, 1993). CPS, which have high 
uronic acid content, may stimulate cytokine production by first binding to CD14 on 
the surface of macrophage. Therefore the interaction between CPS and CD14 may be 
studied further. Furthermore, it is worthy to study the effect ofKl and K24 CPS on 
the upstream regulators of M A P K signaling proteins, including ERK1 and ERK2, 
p38 and JNK, in order to obtain a clear picture of the mechanism of the CPS-induced 
TNF-a production from macrophages. 
< 
K1 and K24 CPS exerted little cytostatic effects on tumor cell line in vitro. 
However, it was found that they could suppress the tumor cell growth in vivo and 
even could prolong the survival of tumor-bearing mice. It is believed that the anti-
tumor activities of CPS are probably mediated through the activation of the host 
immune system rather than resulting from the direct cytotoxicity on tumor cells. The 
anti-tumor activities ofKl and K24 may be contributed to their structures since many 
studies showed that the structure of bioactive compound probably have influence on 
its biological properties. For example, the highly-branched fungal (l—3)-P-D-
glucan, OL-2, isolated from Omphalia lapidescens possess anti-tumor activities 
(Ohno et aL, 1992). The high uronic acid contents in Pseudostellaria heterophylla 
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fractions were found to be related to their immunomodulatory and anti-tumor 
、 activities (Wong et al., 1994). The uronic acid polymers, such as poly mannuronic 
acid, were shown to stimulate cytokine production (Espevik et al., 1993). The high 
uronic acid content of K1 (30.2 %) and K24 (20.2%) may contribute to their 
immunostimulatory and anti-tumor activities. The repeating unit of K24 also 
contains many mannose residues. This may also related to the activities ofK24. The 
structure-function relationship of capsular polysaccharides is worthy for study. The 
structures of K1 and K24 CPS can be modified and tested for their potencies of 
immunomodulatory and anti-tumor activities. These structural modifications include 
reduction of glucuronic acid residues, p-elimination, removal of pyruvic acid side 
chain by mild hydrolysis (only for K1 CPS). This may help to develop a more 
X 
specific and potent compounds in anti-tumor activities. 
The effect of combination of immunotherapy and chemotherapy was studied. 
It was found that the combined treatment of immunotherapy (K1 and K24) and 
chemotherapy (Act D， C Y and Dox) result in additive effect on the in vivo anti-tumor 
activity on EAT growth and prolong the survival of EAT-bearing mice (Chapter 7). 
However, the optimal condition or regimen has not been figured out. It was reported 
that cyclophosphamide has immunopotentiating effect if low dose of 
cyclophosphamide was administered 1 - 2 days before the administration of 
imunotherapeutic drugs (Turk and Parker, 1982). Also, since CPS are polymers, 
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chemotherapeutic drugs may be trapped in the structures of CPS. Hence, the drugs 
could be localized in the tumor site and the cytotoxic effects could be enhanced. 
Therefore, optimal condition or regimen can be figured out by performing the 
experiment with different order of administration of drugs, different methods of 
administration of drugs and different combinations of drugs. 
CPS may reduce the toxic-side effect of chemotherapeutic drug by restoring 
the immunosuppression induced by drug such as cyclophosphamide (Qian et al., 
1997). The immunorestorating activities can be investigated. For example, it is 
worthy to study the effect of CPS in restoring the cyclophosphamide-induced 
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function, production of white blood cell and the growth of spleen and thymus and so 
on. This may result in a better understanding of how CPS can reduce toxic-side 
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